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1. INTRODUCTION 
 
 
 
 
 
In the late 1950s, a genetic defect that caused a severely obese phenotype due 
to overeating and decreased energy expenditure was identified in mice 
(Hausberger et al, 1959). The gene was named ob and the obese mice 
carrying the mutation were called ob/ob (Coleman et al, 1978). In 1994, the 
molecular defect responsible for the obesity syndrome in ob/ob mice was 
identified by Friedman and colleagues (Zhang et al, 1994). The protein 
encoded by the ob gene was named leptin, from the Greek leptos, meaning 
thin. Because a defect in leptin led to overeating and obesity, leptin was 
proposed to be a satiety factor. 
Parabiotic animal experiments suggested that the ob/ob animals were unable 
to make a factor that results in overeating, but ob/ob mice could respond to 
such a factor from a parabiotic mate. Similar experiments suggested that 
db/db mice, which have a mutation in the db gene and display a phenotype 
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identical to ob/ob mice, make the factor that is missing in ob/ob mice, but 
db/db mice cannot respond to it (Fantuzzi and Faggioni, 2000). Therefore, it 
was hypothesized that the db gene would encode for the ob receptor. After the 
cloning of leptin, the leptin receptor (Ob-R) was cloned shortly thereafter by 
virtue of its high affinity to leptin through an expression cloning strategy 
(Tartaglia et al, 1995). The OB-R is indeed the product of the db gene and is 
abundant in the hypothalamus, an area in the brain involved in the control of 
food intake (Lee et al, 1996). 
Thus, both leptin-deficient and leptin receptor-deficient mice display identical 
severe hereditary obesity phenotype, characterized by increased food intake 
and body weight plus decreased energy expenditure (Zhang et al, 1995; 
Montague et al, 1997; Chen et al, 1996). Furthermore, administration of 
leptin reverses the obese phenotype in ob/ob mice and decreases food intake 
in normal mice. In contrast, db/db mice are resistant to the weight-reducing 
effects of leptin (Campfield et al, 1995; Halaas et al, 1995; Pelleymounter et 
al, 1995). 
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1.1. Leptin 
 
Leptin is a 16 kDa protein synthesized mainly by adipose tissue. The 
structure of leptin and its receptor suggest that leptin is a member of the 
cytokine family. Despite the absence of sequence similarity between leptin 
and other long-chain helical cytokines, there is a striking similarity in their 
tertiary structures. Leptin has a four-helix bundle similar to that of the long-
chain helical cytokine family, which also includes IL-6, IL-11, IL-12, 
leukemia inhibitory factor (LIF), G-CSF, CNTF, and oncostatin M (Zhang et 
al, 1997). 
Circulating leptin levels are directly related to adipose tissue mass (Frederich 
et al, 1995). High leptin levels signal the presence of sufficient energy stores 
to sites in the central nervous system, which respond by reducing appetite and 
increasing energy expenditure, preventing severe obesity (Maffei et al, 1995). 
Therefore, leptin signals the nutritional status from the periphery to the area 
of the brain involved in the homeostasis of energy balance (Faggioni, 2001). 
Leptin, initially discovered as a regulator of food intake and energy 
expenditure, is emerging as a pleiotropic molecule involved in a variety of 
physiological and pathological conditions. A pleiotropic role for leptin in 
mammalian physiology is clearly suggested by the complex syndrome 
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exhibited by leptin-deficient ob/ob mice and leptin receptor-deficient db/db 
mice. Those mice are not only obese, but have abnormalities in reproductive 
function, hormone levels, wound repair, bone structure, and immune function 
(Flier, 1998).  
 
1.2. Leptin receptor 
 
The Ob-R is a cytokine receptor and belongs to the class I cytokine receptor 
family that includes gp-130, the common signal-transducing component for 
the IL-6-related family of cytokines (Tartaglia et al, 1995). The Ob-R is 
alternately spliced into at least five transcripts from the single db gene. These 
transcripts encode proteins called the long (Ob-Rb), short (Ob-Ra, -c, and -d), 
and soluble (Ob-Re) forms of the leptin receptor with varying length of their 
cytoplasmic tail (Lee et al, 1996). The complexity of the Ob-R system is 
typical of cytokine biology, where the signal triggered by the binding of a 
cytokine to its receptor on target cells might be modulated by soluble 
receptors, decoy receptors, receptor antagonists, and binding proteins. 
The long form is essential in mediating most of the biological effects of leptin 
(Lee et al, 1996; Chen et al, 1996). Ob-Rb is highly expressed in the 
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hypothalamus (Vaisse et al, 1996), but is also present in peripheral tissues, 
including those of the immune system such as spleen, thymus, lung, and 
leukocytes (Tsuchiya et al, 1999; Lord et al, 1998; Cioffi et al, 1996). 
The short isoform (Ob-Ra) is the most abundant isoform found in most 
tissues (Tartaglia et al, 1995). It is highly expressed in the choroid plexus 
where it is likely to function as a transporter across the blood–brain barrier 
(Kastin et al, 1999). Although evidence of signaling capabilities has been 
reported for Ob-Ra (Bjorbaek et al, 1997), the complete role of the signal it 
triggers is still unclear; it remains to be determined whether it might also 
function as a decoy receptor or have a role as a ligand-passing receptor. 
Leptin circulates both in free form and bound to its soluble receptor Ob-Re 
(Sinha et al, 1996). Ob-Re appears to act as a carrier, since the binding of 
leptin to it delays its clearance from circulation and potentiates its effect on 
food intake (Huang et al, 2001). Other cytokine receptors, such as tumor 
necrosis factor (TNF), also use their soluble receptors as binding proteins 
(Engelmann et al, 1990). 
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1.2.1. Leptin receptor signaling 
 
Ob-Rb contains an extracellular ligand-binding domain, a single 
transmembrane domain, and a cytoplasmic signaling domain (Tartaglia, 
1997). Ob-Rb shares the same signal transduction pathway with gp-130-like 
cytokines (Baumann et al, 1996). It activates Janus kinase/signal transducers 
and activators of transcription (STAT) as well as mitogen-activated protein 
kinase signal transduction pathways (Vaisse et al, 1996). In common with 
cytokine-transducing pathways, leptin induces expression of SOCS 
(suppressor of cytokine signaling)-3 mRNA in the hypothalamus. SOCS 
proteins are thought to function as inducible intracellular negative regulators 
of cytokine signal transduction. Accordingly, transfection data suggest that 
SOCS-3 is an inhibitor of leptin signaling (Bjorbaek et al, 1999). 
Unliganded Ob-Rb exists as a preformed homodimer; leptin binding alters 
the conformation of the Ob-Rb dimer, enabling transphosphorylation and 
activation of the intracellular Ob-Rb-associated Janus associated kinases-2 
(Jak2) molecules (Devos et al, 1997). The activated Jak2 molecule then 
phosphorylates other tyrosine residues within the Ob-Rb/Jak2 complex to 
mediate downstream signaling (White et al, 1997). 
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All the four membrane-bound leptin receptors contain in the cytoplasmic tail 
a box 1 motif, strongly conserved within most members of this receptor 
family, whereas box 2 and 3 motifs are found only in the long isoform. 
Domains 1 and 2 are involved in the interaction and activation of JAK2 
tyrosine kinase that phosphorylates and activates members of the STAT 
family of transcription factors, such as STAT1, STAT3 and STAT5. The 
activation of STAT3 has been observed in vivo in the hypothalamus and 
requires a box 3 motif in the receptor intracellular domain (Vaisse et al, 
1996). These transcription factors, after tyrosine-phosphorylation in response 
to JAK activation, translocate to the nucleus, where they activate gene 
transcription.  
 
1.3. Leptin and inflammation 
 
In addition to its well-defined role as regulator of energy balance, leptin 
appears to be involved in the host response to infection and inflammation 
(Fantuzzi and Faggioni, 2000). In fact, leptin levels are up-regulated by many 
acute phase factors, such as TNF, IL-1 and IL-6, and during bacterial 
infection, or lipopolysaccharide challenge (Faggioni et al, 2001). Leptin, per 
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se, acts on monocytes/macrophages by inducing eicosanoids synthesis, nitric 
oxide and several pro-inflammatory cytokines (Mancuso et al, 2004). In 
addition, this hormone potentiates IFN-γ-induced expression of nitric oxide 
synthase and cyclo-oxygenase-2 in murine macrophage J774A.1 (Raso et al, 
2002). Moreover, leptin induces chemotaxis of neutrophils, the release of 
oxygen radicals (Caldefie-Chezet et al, 2001), and also affects natural killer 
(NK)-cell development and activation both in vitro and in vivo (Tian et al, 
2002).  
Leptin has been demonstrated also to modulate adaptive immune response. 
This is divided classically into T helper 1 and 2 immune responses on the 
basis of the cytokine pattern produced. T helper 1 lymphocytes produce 
mainly pro-inflammatory cytokines that are necessary for macrophage 
activation and cell-mediated response, whereas T helper 2 lymphocytes 
secrete modulatory and anti-inflammatory peptides that are important factors 
for the activation of B cells and basophils. It has been found that leptin 
deficiency is responsible for the immunosuppression and thymic atrophy 
observed during acute starvation and reduced caloric intake. The impairment 
of the immune response is associated with a dramatic fall in serum leptin and 
in rodents is reverted by exogenous leptin. In mice leptin is necessary for an 
effective cell-mediated immunity and the CD4+ T lymphocytes function is 
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suboptimal in the absence of leptin as observed in ob/ob mice (Lord et al, 
1998). In addition, there are several evidences that leptin participates in the 
maintenance of thymic maturation of double positive CD4+/CD8+, cells and 
prevents glucocorticoids-induced apoptosis in thymocytes (Howard et al, 
1999).  
 
1.4. Inducible nitric oxide synthase 
 
In mammals, three distinct isoform of nitric oxide synthase (NOS) exist: 
neuronal (nNOS or NOS1), inducible (iNOS or NOS2), and endothelian 
(eNOS or NOS3). nNOS and eNOS are primarily expressed in neurons and 
endothelian cells, respectively. iNOS expression is induced in a wide range of 
cells and tissues by cytokines and other agents. After induction, iNOS 
produces continuosly NO until the enzyme is degraded (MacMicking et al, 
1997). 
Although, NO production by iNOS has been described to have benefical 
immunological effects (MacMicking et al, 1997), aberrant iNOS induction 
seems to be involved in the patholophysiology of human diseases such as 
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asthma, arthritis, multiple sclerosis, neurodegenerative diseases, or septic 
shock (Bogdan, 2001; Kroncke et al, 1998). 
No data report a direct iNOS induction by leptin, although we have 
previously demonstrated that in a macrophage cell line J774A.1 leptin 
synergized with IFN-γ in NO and PGE2 release, increasing iNOS and COX-2 
expression (Raso et al, 2002). Moreover in human primary chondrocytes and 
ATDC5 cells IFN-γ-induced iNOS expression was increased by leptin and 
occurred via activation of JAK-2 (Otero et al, 2003). 
 
1.4.1. Regulation of iNOS expression 
 
The pathways regulating iNOS expression seem to vary in different cells or 
species. Activation of the transcription nuclear factor (NF)-kB and signal 
transducer and activator of transcription (STAT)-1α seems to be an essential 
step in the regulation of iNOS expression in most cells (Kleinert et al, 2004). 
In particular, the transcriptor factor NF-kB seems to be a central target for 
activators or inhibitors of iNOS expression. It has been shown that tyrosine 
phosphorylation of JAK-2 and the activation of NF-kB by several cytokines 
were required for iNOS induction in rat glial cells, C6 (Nomura, 2001). 
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NF-kB activation is regulated by a related inhibitory protein called IkB 
(Blackwell and Christman, 1997; Ghosh et al, 1998; Karin and Delhase, 
2000). The IkBα isoform retains NF-kB in the cytoplasm by masking its 
nuclear translocation sequences under basal conditions. In response to a 
proinflammatory signal, IkB-α is rapidly phosphorylated by IKB kinase 
(IKK), thus targeting IkBα for polyubiquitination and degradation by the 26S 
proteasome. Proteolytic processing of IkB-α by the proteasome complex 
(26S) unmasks NF-kB nuclear translocation sequences, thus allowing NF-kB 
to enter the nucleus for direct transcription of specific pro-inflammatory 
genes. 
 
1.5. Astrocytes and inflammation 
 
There are two groups of glial cells in the central nervous sistem: microglia 
and macroglia, the latter of which includes astrocytes, oligodentrocytes, and 
ependymal cells. Astrocytes are the major glial cells and have a number of 
important physiological properties related to CNS homeostasis. Astrocytes 
affect neuronal function, guide neuronal development and play a significant 
role during infections and autoimmuno diseases of the CNS. 
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Astrocytes, as part of the blood–brain barrier (BBB), are in close proximity to 
endothelial cells; they also secrete cytokines, and present antigens to T-cells 
(Dong and Benviste, 2001). In particular, expression of inflammatory 
cytokines by astrocytes is an important regulator of brain response to injury 
and infection.  
In the CNS, inducible or immunological NOS is mainly expressed in 
activated astrocytes and microglia after ischemic, traumatic, neurotoxic or 
inflammatory damage in rodents and humans (Lee et al, 2003). 
High levels of NO induced by these stimuli and different mediators, such as 
cytokines locally released, are implicated in several diseases: NO production 
contributes to oligodendrocyte degeneration (Merrill et al, 1993), neuronal 
injury during trauma (Uehara et al, 1999a) and cerebral ischemia (del Zoppo 
et al, 2000). 
Evidence suggests that leptin may be a risk indicator for ischemic and 
hemorrhagic stroke in patients of both sexes (Soderberg et al, 1999; 2003). 
Moreover, cytokines seem to be important modulators of neuroendocrine 
disturbances, including diurnal rhythmicity of cortisol and leptin, which are 
common and often profound soon after strokes (Johansson et al, 2000). 
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1.6. Aim of the study 
 
The long form of the receptor, Ob-Rb, has a cytoplasmatic region with 
consensus aminoacid sequences involved in receptor binding to Jak-STAT 
tyrosine kinases (Vaisse et al, 1996; McCowen et al, 1998). It has been 
shown that tyrosine phosphorylation of Janus associated kinases-2 and NF-
kB activation by IFN-γ are required for the induction of iNOS in C6 
astroglioma cells (Nishiya et al, 1995). 
High levels of NO induced by different stimuli, such as cytokines, can be 
cytotoxic and play a critical role in the brain. NO derived from iNOS 
activation in glial cells is involved in neuronal cell death (Uehara et al, 1999).  
Since a close relationship appears to exist between inflammation, cytokines, 
and gliosis, the purpose of this study was to analyze the modulation by leptin 
of iNOS expression induced by inflammatory cytokines in C6 cells. 
Moreover, considering the role of NF-kB in the regulation of iNOS, we 
investigated the effect of pyrrolidine dithiocarbamate (PDTC) and N-α-tosyl-
L-lysine chloromethyl ketone (TLCK), two NF-kB pathway inhibitors, on 
leptin-induced iNOS expression. 
The antioxidant PDTC is thought to inhibit NF-kB activation by depleting the 
cells of oxygen radicals. TLCK is a serine protease inhibitor and its site of 
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action appears to be at the proteasome complex (26S), although TLCK may 
have other sites of action. Conversely, MG132 is a potent and specific 
inhibitor of the proteasome complex, and hence of IkB-α degradation 
(Sherman et al, 1993; Kim et al, 1995; Epinat and Gilmore, 1999). We 
therefore evaluated the degradation of IkB-α, which is necessary for NF-kB 
activation, after hormonal stimulation with or without MG132. 
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2. MATERIALS AND METHODS 
 
 
 
2.1. Cell culture and treatments 
 
C6 glioma cell line was cultured in 75-cm2 flasks in Dulbecco’s modified 
essential medium (DMEM) with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37°C under 5% CO2 humidified air. 
Cells were passaged at confluence using a solution of 0.025% trypsin and 0.01% 
EDTA. Cells were cultured for 3 days to confluence in complete medium. After 
12 h of starvation in serum free 5 DMEM/F12, cells were stimulated with leptin 
(filtered with Detoxi-gelTM columns in order to remove pyrogens). Our 
protocol utilized hormone concentrations that produced detectable NO release. 
The hormone (NIDDK’s National Hormone & Peptide Program; 1, 3, or 10 
µg/ml) was used alone or in combination with IFN-γ (Calbiochem; La Jolla, CA, 
USA; 200 U/ml), or TNF-α (Sigma, St. Louis, MO, USA; 500 U/ml), or IFN-γ 
(100 U/ml) plus IL-1β (Calbiochem; 10 ng/ml). After 22 h of incubation the 
supernatants were analyzed for NOx assay. The effect of PDTC (Sigma, St. 
Louis, MO, USA; 10, 50, and 100 µM), TLCK (Sigma; 10, 30 and 50 µM), and 
MG132 (Sigma; 1, 5, and 10 µM) on iNOS induction was assessed by adding 
them 60 min before leptin stimulation. To evaluate the temporal effect of leptin 
on IkB-α degradation, C6 cells were stimulated with leptin (10 µg/ml) for the 
indicated time periods (0-5-15-30-45-60-90 and 120 min) in the absence or 
presence of MG132 (10µM). 
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 2.2. Measurement of nitrite and nitrate (NOx) on the supernatants 
 
NOx production was measured in the culture medium. Briefly, the nitrate in the 
samples was first reduced to nitrite by incubation with nitrate reductase (670 
mU/ml) and NADPH (160 µM) at room temperature for 3 h. The nitrite 
concentration in the samples was then measured by the Griess reaction, by 
adding 100 µl of Griess reagent (0.1% (w/v) naphtylethylenediamine-HCl and 
1% (w/v) sulphanilamide in 5% (v/v) phosphoric acid (vol.1:1) to 100 µl 
samples. The optical density at 550 nm was measured using a microplate reader 
Titertek. Nitrite concentrations were calculated from a sodium nitrite standard 
curve freshly prepared in culture medium and expressed as micromolar unit. 
 
 
 2.3. Semi-quantitative RT-PCR 
 
After 22 h of cell stimulation total RNA was extracted by a modified method of 
Chomczynski and Sacchi (1987), using TRIzol Reagent (Life Technologies, 
Milan, Italy) according to the manufacturer’s instructions. Reverse transcription 
was performed by a standard procedure (Brenner et al., 1989) using 2 µg of total 
RNA. After reverse transcription, 2 µl of RT products were diluted 6 in 48 µl of 
PCR mix, to give a final concentration of 50 U/ml of Taq DNA polymerase 
(Promega, Madison, WI, USA) 4 µM of 5’ and 3’ primers, 50 µM of each 
dNTP, 1.5 mM MgCl2, and 1x PCR buffer (20 mM Tris-HCl, pH 8.4, 50 mM 
KCl). The following oligonucleotides were used: 
 iNOS; 5’-TGCCCCTTCAATGGTTGGTA-3’  
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5’-ACCGGAGGGACCAGCCAAAT-3’   
cyclophilin: 5’-CGACATCACGGCTGATGGCGAGCCC -3’ 
5’-TTACAGGGTATTGCGAGCAGATGGGG-3’. 
iNOS and cyclophilin cDNAs underwent 28 cycles, each one performed at 94°C 
for 1 min, Tm 60°C for 1 min, and 72°C for 1 min. After this treatment 10µl of 
RT-PCR products were separated by 1.5% agarose gel electrophoresis in TBE 
1X (Tris-base 0.089 M, boric acid 0.089 M) containing 0.2 µg/ml of ethidium 
bromide. Fragments of DNA were seen under UV light. Cyclophilin was used as 
an internal reference and no bands were observed in absence of cDNA. 
 
 
2.4. Western blot analysis 
 
For protein detection, cells were washed twice with ice-cold phosphate-buffered 
saline (PBS) and resuspended in Tris-HCl 20 mM pH 7.5, 10 mM NaF, 150 mM 
NaCl, 1% Nonidet P40, 1 mM phenylmethylsulphonylfluoride, 1 mM Na3VO4, 
leupeptin (10 µg/ml), and trypsin inhibitor (10 µg/ml). After 40 min, cell lysates 
were obtained by centrifugation at 100,000 g for 15 min at 4°C. 
Protein concentrations of cell lysates were estimated by the Bio-Rad protein 
assay using bovine serum albumin as standard. 
Equal amounts of protein of the cell lysates were dissolved in Laemmli's sample 
buffer, boiled for 5 min, and subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (8% and 12 % polyacrylamide for iNOS and 
IkB-α detection, respectively). Western blotting was performed by transferring 
proteins from slab gel to a sheet of nitrocellulose membrane at 240 mA for 40 
min at room temperature. The filters were then blocked with 1X PBS and 5% 
non-fat dried milk for 40 min at room temperature and incubated with the 
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specific monoclonal antibody IgG1 anti-iNOS (Transduction Laboratories, 
Lexington, KY, USA; 1:10,000) or anti-IκB-α (SC-371; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA; 1:1,500) antibody in 1X PBS, 5% non-fat 
dried milk and 0.1% Tween 20 overnight at 4°C. Thereafter, the filters were 
incubated with the appropriate secondary antibody (anti-mouse or anti-rabbit 
IgG horseradish peroxidase conjugates; Jackson, West Grove, PA, USA) for 1 h 
at room temperature. 
The antibody-reactive bands were revealed by chemiluminescence (ECL). To 
ascertain that blots were loaded with equal amounts of protein lysates, they were 
also incubated in the presence of the antibody against the β-actin protein. The 
protein bands on X-ray film were scanned and densitometrically analyzed by 
Model GS-700 Imaging Densitometer. 
 
 
2.5. Statistical analysis 
 
Data are presented as mean ± SEM values of 3 independent determinations. All 
experiments were done at least three times, each time with three or more 
independent observations. Statistical analysis was performed by two-way 
ANOVA test and multiple comparisons were made by Bonferroni’s test. A value 
of P<0.05 was considered significant. 
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3. RESULTS 
 
 
3.1. Effect of leptin alone or in cytokine combination on NOx production 
 
Leptin (1-3-10 µg/ml) induced NO accumulation in C6 supernatant (control was 
1.11±0.53, leptin was 2.92±0.23, 3.41±0.24, and 4.78±0.02 µM at 1, 3, 10 
µg/ml, p<0.05, p<0.01 and p<0.001 vs control, respectively). Moreover leptin 
potentates IFN-γ (200 U/ml)-induced NOx release in a concentration-dependent 
manner and this synergistic effect was significant at 3 and 10 µg/ml of leptin 
(Fig.1, p<0.001, vs IFN-γ alone). As shown in Fig.2, leptin also in combination 
with TNF-α potentiates cytokine-induced NO release. This effect was 
concentration-dependent and significant at 3 and 10 µg/ml of leptin (p<0.05 and 
p<0.001 vs TNF-α alone, respectively). IL-1β did not induce NO release (data 
not shown), but when it was associated with leptin (3 or 10 µg/ml) a significant 
increase of NO production was evidenced (7.80±0.10 and 12.50±0.08 p<0.05 
and p<0.01 vs leptin alone). Moreover, when a lower concentration of IFN-γ 
(100 U/ml) was added to IL-1β (10 ng/ml) a synergistic effect was evident using 
3 and 10 µg/ml leptin (Fig. 3, #p<0.05 vs cytokine combination). 
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Fig. 1  Evaluation of NO production by C6 cells stimulated for 22 h with 
leptin (1, 3, and 10 µg/ml) in combination with IFN-γ (200 U/ml).  
The values expressed as NOx (µM) are means of at least 3 
determinations ± SEM. *p<0.05 and ***p<0.001 vs control; ### 
p<0.001 vs IFN-γ alone. 
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Fig. 2  Evaluation of NO production by C6 cells stimulated for 22 h with 
leptin (1, 3, and 10 µg/ml) in combination TNF-α (500 U/ml).  
The values expressed as NOx (µM) are means of at least 3 
determinations ± SEM. # p<0.05 and ### p<0.001 vs TNF-α alone. 
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Fig. 3  Evaluation of NO production by C6 cells stimulated for 22 h with 
leptin (1, 3, and 10 µg/ml) in combination with or IFN-γ (100 U/ml) plus 
IL-1β (10 ng/ml).  
The values expressed as NOx (µM) are means of 3 determinations ± 
SEM. *p<0.05 vs control; # p<0.05 vs IFN-γ and IL-1β combination. 
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3.2. Leptin induced iNOS and potentated cytokine-induced protein expression 
 
To determine whether leptin effect on NO release was related to enhanced 
iNOS expression, RT-PCR and Western blot analysis were carried out. 
Representative RT-PCR and blot of RNA extracts and lysates obtained from 
cells stimulated with leptin alone or in combination with different cytokines 
are shown in Fig. 4. 
In unstimulated control cells iNOS expression was not detectable. Using 
semi-quantitative RT-PCR and Western blot analysis, we showed a 
concentration-dependent increase of iNOS (305 bp or 130 kDa) expression 
after leptin stimulation. IFN-γ and TNF-α by themselves, as well as leptin 
induced iNOS in mRNA and protein. The cytokine effect was up-regulated 
by increasing concentration of leptin (Fig.4 panel A and B). A synergistic 
effect was observed when leptin was used in combination with IL-1β and, 
interestingly, it was increased by a lower concentration of IFN-γ (Fig.4 panel 
C).  
Cyclophilin was used as internal reference for RT-PCR analysis, while to 
ascertain that blots were loaded with equal amounts of protein lysates, they 
were also incubated in the presence of the antibody against the β-actin protein 
(data not shown). 
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Fig. 4 Leptin induction of iNOS expression and its potentation by cytokines. 
Representative semiquantitative RT-PCR (A,B,C upper panels) and Western blot analysis 
(A,B,C lower panels) of extracts and lysates prepared by unstimulated and stimulated cells 
with the hormone alone and in combination with different cytokines are shown. iNOS 
mRNA band was found at 305 bp and protein band corresponded to 130 kDa. Similar 
results were obtained in three additional separate experiments. 
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3.3. Inhibition of leptin induced iNOS by NF-kB inhibitors 
 
The possible role of NF-kB pathway in the regulation of iNOS expression by 
leptin was examined using two well known inhibitors: PDTC and TLCK 
(Fig.5 and Fig.6). Leptin effect was markedly reduced by both inhibitors. In 
particular TLCK was more active than PDTC as evidenced by the 
concentration-dependent inhibition of the enzyme induction. 
To confirm NF-kB role in leptin-induced enzyme expression, we used the 
more potent and specific membrane-permeable proteasome inhibitor MG132 
(Fig. 7). The pre-treatment of cells with this drug (1-10 µM) inhibited 
concentration-dependent leptin-induced iNOS. Lower panels of figure 5, 6 
and 7 showed densitometric analysis of protein bands obtained from three 
separate experiments. 
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Fig. 5 Effect of PDTC on leptin-induced iNOS expression. Representative 
Western blot analysis is shown. PDTC (10-50-100 µM) was added 1 h before 
leptin stimulation (10 µg/ml). Respective densitometric analysis of protein bands 
is reported in lower panels and obtained from three separated experiments 
(***p<0.001 vs leptin). 
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Fig. 6 Effect of TLCK on leptin-induced iNOS expression. Representative 
Western blot analysis is shown. TLCK (10-30-50 µM) was added 1 h before 
leptin stimulation (10 µg/ml). Respective densitometric analysis of protein bands 
is reported in lower panels and obtained from three separated experiments 
(***p<0.001 vs leptin). 
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Fig. 7 Effect of MG132 on leptin-induced iNOS expression. A 
representative Western blot analysis is shown (upper panel). MG132 (1-5-
10 µM) was added 1 h before leptin (10 µg/ml). 
Respective densitometric analysis of protein bands is reported in lower 
panel and obtained from three separated experiments (***p<0.001 vs 
leptin).
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3.4. Time-course of the effects of leptin on the IκB-α degradation 
 
IkB-α degradation was evaluated after hormonal stimulation by Western blot 
analysis (band at 37 kDa) at the indicated sampling times (0-120 min). The 
levels of IkB-α were decreased after 5-15 min in response to leptin and 
restored at 30 min, returning to basal level (Fig. 8). Next we examined the 
effect of MG132 on leptin-induced IkB-α degradation. Pre-treatment of C6 
cells with this inhibitor reverted the protein degradation of the protein 
induced by leptin both at 5 and 15 min (Fig. 9). 
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Fig. 8 Effect of leptin (10 µg/ml) on IkB-α degradation at the indicated 
sampling times (0-120 min). A representative immunoblot analysis of 
three independent experiments is shown (***p<0.001 vs control lane). 
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Fig. 9 MG132 (10 µM) reverses IkB-α degradation induced by leptin 
(10 µg/ml). A representative immunoblot analysis of three independent 
experiments is shown. 
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4. DISCUSSION 
 
 
In our study, we report that in vitro leptin stimulation increases NO 
production and potentiates the effects induced by different Th1 cytokines, 
modulating the inflammatory properties of astrocytes, which represent the 
most abundant glial cell type in the CNS. 
Using C6 cells we found that leptin increases iNOS derived NO production 
and enzyme expression both alone and in combination with IFN-γ, TNF-α, or 
IFN-γ/IL-1β. Since NO production is proportional to cell number, we 
excluded the possible interference of a proliferative effect by leptin on NO 
release using MTT assay (Raso et al, 2002): no change in cell proliferation 
was evident when C6 were treated with the used concentrations of leptin 
alone or in combination with all tested cytokines (data not shown). The 
regulation of iNOS gene expression is complex; several data indicate that it is 
primary under a transcriptional control mechanism and that transcription 
factors, such as NF-kB, AP-1, and STAT1α may function synergistically 
(Taylor and Geller, 2000; Nomura, 2001). 
In C6 cells several studies showed that iNOS induction by LPS in presence of 
cytokines required more than one signal pathway. In particular TNF-α and 
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LPS stimulation involves NF-kB and AP-1 (Lee et al, 2003), while LPS and 
IFN-γ activate NF-kB and JAK-2/STAT1α, respectively. 
We have demonstrated for the first time that leptin-induced iNOS expression 
was dependent from NF-kB activation. In fact, both TLCK and PDTC 
inhibited enzyme expression induced by the hormone, suggesting a role for 
this transcriptional factor. Although different mechanisms underlined the 
activity of these inhibitors (Xie et al, 1994; Schreck et al, 1992), both 
compounds have been shown to inhibit iNOS expression induced by leptin in 
a concentration-dependent manner. In particular TLCK, that blocks early 
events of iNOS induction preventing IkB degradation, appears to be more 
active than PDTC, which acts by anti-oxidant properties. 
Since proteasome inhibition is known to inhibit NF-kB via blocking IkB 
degradation (Haas et al, 1998), the cells were also treated with MG132, a 
specific proteasome inhibitor. MG132 reduced leptin-induced iNOS 
expression in a concentration-dependent manner. 
After the rapid translocation of NF-kB, this factor binds to kB DNA motifs 
present in a variety of promoter regions including that of iNOS (Xie et al, 
1994), as well as of IkBα (Simeonidis et al, 1999). The de novo transcription 
of IkB-α results in its rapid protein expression, which can reassociate with 
active cytoplasmatic and nuclear NF-kB, reducing the ongoing NF-kB 
activity. 
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Thus we investigated the effect of leptin on IkB-α degradation: the hormone 
processes this protein, that is rapidly resynthesized at 30 min, most likely 
through the positive regulation of its transcription by NF-kB. In addition the 
pretreatment with MG132 caused an accumulation of IkB-α 
IkB-α, completely preventing hormonal-induced protein degradation at 5 and 
15 min. All cytokines used potentiated the induction of iNOS by leptin and 
this effect was more evident when the hormone was in presence of IFN-γ. As 
reported, it was previously shown in primary condrocytes and ATDC5 cells 
that IFN-γ induced iNOS expression was increased by leptin (Otero et al, 
2003). Since both the functional isoform of Ob-R and the INF receptor signal 
via JAK/STAT pathway, the authors argued that leptin potentiation occurs by 
this same pathway, without excluding the involvement of other transcription 
factors. However, in their experimental conditions leptin alone failed in iNOS 
induction. 
Our data demonstrate a role for NF-kB in hormone activity and we suggest 
that leptin-activated NF-kB can cooperate with the JAK-2/STAT1α pathway 
induced by IFN-γ to promote the transcription of iNOS. In fact, when MG132 
was added to cells stimulated with leptin and IFN-γ we observed a significant 
but partial reduction of iNOS expression (data not shown). 
The hormone synergized iNOS expression also in combination with other 
pro-inflammatory cytokines such as TNF-α or IL-1β. Although these 
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cytokines are known to signal through NF-kB by proteosome activation (Hu, 
2003; Uehara et al, 1999b), the mechanism of the potentiating effect of leptin 
on iNOS induction needs further studies. Interestingly the hormone is able to 
induce an evident increase of NO production when added to IL-1β, which 
was inactive itself. 
Hence leptin, in addition to its well defined role as an adipostat hormone, 
may be considered a paracrine and/or autocrine mediator of neuroendocrine 
physiopathological functions and may cooperate in turn with cytokines to 
amplify and/or sustain CNS inflammation. 
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 OF ENERGY BALANCE 
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5. INTRODUCTION 
 
 
 
 
For more than a century, increasingly sophisticated methods have been 
applied to identify and isolate the brain’s role in the regulation of energy 
metabolism. 
In the 1940s and 1950s, the hypothalamus emerged as one of the critical sites 
for energy homeostasis during degeneration studies. Destruction of the 
hypothalamic ventromedial, paraventricular, and dorsomedial nuclei induced 
abnormal increase in appetite and food intake (hyperphagia; Hetherington, 
1942). By contrast, lesions of the lateral hypothalamus reduced food intake 
(hypophagia; Anand, 1951).  
The idea that the CNS, and the hypothalamus in particular, is key in 
metabolism regulation was reinforced by the discovery of leptin. Since the 
identification of leptin, there has been a considerable effort in research to 
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identify the neural circuits that mediate the effects of adiposity signals in the 
CNS to limit food intake and elevate energy expenditure. Dozens of 
neurotransmitter systems with actions in the hypothalamus and other brain 
regions have been identified that influence food intake and body weight. An 
important challenge is to organize all of them into functional circuits to 
identify opportunities to intervene and produce significant and sustained 
weight loss. 
 
 
5.1. Hypothalamic circuits 
 
The hypothalamus consists of several nuclei involved in food intake. In the 
arcuate nucleus (ARC), neurons are located at the bottom of the 
hypothalamus around the third ventricle in direct contact with peripheral 
satiety factors like leptin and insulin. In the median eminence (ME), which 
overlies the ARC, the blood brain barrier (BBB) is not present, and, while the 
neuronal cell bodies in the ARC are protected by the BBB, the axon terminals 
are in direct contact with the bloodstream (Peruzzo et al, 2000). For this 
reason, they are called ‘first order neurons’. 
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The ARC contains at least two distinct groups of neurons controlling energy 
balance, one as neurons that contain the orexigenic neuropeptides agouti-
gene-related protein (AgRP) and neuropeptide Y (NPY), and two as neurons 
that contain the anorexigenic neuropeptides pro-opiomelanocortin (POMC) 
and cocaine- and amphetamine-regulated transcript (CART). From the ARC, 
neurons project to ‘second order neurons’ in the paraventricular nucleus 
(PVN), the ventromedial nucleus (VMH), the dorsomedial nucleus (DMH), 
and in the lateral hypothalamic area (LHA; Schwartz, 2000). 
NPY/AgRP and melanocortinergic neurons are also found to connect with 
neurons that synthesize other regulators of energy homeostasis, such as 
melanocortin-concentrating hormone (MCH) and orexin neurons in the LH, 
which is also named the ‘feeding center’ (Elias et al, 1998). ‘Second order 
neurons’ project to, among others, the nucleus of the solitary tract (NTS) in 
the brainstem and the dorsomotor nucleus of the vagus (DMV). This 
communication between hypothalamic pathways and the caudal brainstem, 
responding to meal-related satiety signals, is essential for long-term 
regulation of energy homeostasis (Hillebrand et al, 2002). 
These hypothalamic regions contain the highest concentration of leptin 
receptors in the brain, numerous insulin receptors, and also binding sites for 
glucocorticoids, ghrelin and other peripheral signals, suggesting an important 
role of this cell group in converting information about metabolic balance 
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from the periphery to the brain. Peripheral hormones influence energy 
homeostasis either by activating or inhibiting the activity of the orexigenic or 
anorexigenic peptides within the hypothalamus (Sainsbury et al, 2002). 
 
 
5.2. The CNS melanocortin system 
 
The melanocortin system was first linked to the control of skin and hair 
pigmentation. Several important melanocortin receptor ligands come from the 
precursor peptide proopiomelanocortin (POMC). In particular, alpha-
melanocyte-stimulating hormone (α-MSH) acts on the first of five identified 
melanocortin receptor subtypes (MC1) located primarily in the skin and hair 
to produce dark pigmentation. A second melanocortin ligand produced from 
POMC is adrenocorticotrophic hormone (ACTH). ACTH is produced in the 
pituitary as an essential part of the stress response. ACTH circulates in the 
blood and acts upon MC2 receptors found primarily in the adrenal gland to 
stimulate glucocorticoid secretion (Grill et al, 1998). POMC and α-MSH  
appear ideally situated to be critical regulators of both food intake and energy 
expenditure. α-MSH is a potent for agonist not only MC1 receptors but also 
for MC3 and MC4 receptors that are found primarily within the CNS. 
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Although MC3 receptors have a rather narrow distribution within specific 
subregions of the hypothalamus, MC4 receptors are broadly distributed in the 
CNS, including several regions of the hypothalamus, and are also found in 
the nucleus accumbens and the dorsal motor nucleus of the vagus (Kishi et al, 
2003; Liu et al, 2003). 
AGRP is a competitive antagonist/inverse agonist of MC4 receptors (MC4R) 
in the CNS, so its actions oppose those of α-MSH. Consistent with its 
important role as an anabolic effector, AGRP expression is increased in 
fasting and leptin-deficient mice (Haskell-Luevano et al, 2001). Both the 
POMC and the AGRP/NPY neurons in the arcuate are the main regulators of 
appetite, satiety, and the regulation of energy expenditure. The POMC cells 
maintain an anorexigenic tone, whereas the NPY/AGRP neurons maintain an 
orexigenic tone (Sommer et al, 1967). In this model, activation of POMC 
neurons by leptin triggers the release of α-MSH from POMC axon terminals, 
which in turn activates MC4R, leading to suppressed food intake and 
increased energy expenditure. Simultaneously, leptin suppresses the activaty 
of arcuate nucleus NPY/AgRP neurons (Cowley et al, 2001), which 
otherwise would antagonize the effect of α-MSH on MC4Rs through the 
release of AgRP (Ollmann et al, 1997).  
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Other peripheral peptides have been hypothesized to act directly upon 
melanocortinergic neurons in the arcuate. For example, the stomach makes a 
peptide called ghrelin that, when given either peripherally or directly into the 
CNS, stimulates food intake. Consistent with this action of ghrelin, 
circulating levels of ghrelin are increased after periods of fasting and 
decreased during feeding, the opposite of leptin (Horvath et al, 2001; Inui, 
2001). Moreover, ghrelin reduces activity in POMC neurons via actions on 
ghrelin receptors, also termed growth hormone secretagogue receptors 
(Cowley et al, 2003). Additionally, circulating levels of peptide YY(3-36) 
[PYY(3-36)] are increased after meals, and peripheral or interarcuate 
injections of PYY(3-36) have been reported to reduce food intake. PYY(3-
36) also results in increased activity of POMC neurons (Batterham et al, 
2002). These data support the hypothesis that a variety of circulating 
peripheral factors may act upon melanocortin neurons in the arcuate in order 
to mediate control of energy balance. 
 
5.3. Thyroid hormones 
 
Thyroxine (T4) and triiodothyronine (T3) are essential for normal 
development, differentiation, and metabolic balance. Normally, thyrotropin-
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releasing hormone (TRH), a product of the hypothalamus, stimulates the 
pituitary gland to secrete thyroid-stimulating hormone (TSH). TSH activates 
the thyroid gland to secrete T3 and T4. Quantitatively, T4 is the largest 
hormone secreted, but T3 is the active hormone. The major source of 
circulating T3 is the peripheral conversion of T4 to T3 by iodothyronine 
deiodinases. Thyroid hormones travel in the bloodstream linked to the carrier 
proteins, T4-binding globulin (TBG), transthyretin, and T4-binding 
prealbumin. Free T3, the unbound hormone, mediates the cellular action of 
the thyroid gland. In target cells, thyroid hormone binds to nuclear receptors 
that alter the expression of specific genes (Zhang, 2000).  
 
5.3.1. Thyroid hormone receptors 
 
Thyroid Receptors (TRs) belong to the nuclear receptor superfamily that also 
includes the receptors for retinoids, vitamin D, fatty acids, and 
prostaglandins, as well as "orphan receptors" with no identified ligands 
(Evans, 1988; Mangelsdorf et al, 1995; Ribeiro et al, 1995). TR is encoded by 
two separate genes, designated TRα and TRβ, located in different 
chromosomes (17 and 3, respectively, in humans). Alternative splicing from 
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each gene generates multiple TR isoforms, including TR α1, TR α2, and TR 
α3 from the TRα gene, and TRβ1 and TRβ2 from the TRβ gene (Lazar, 
1993). 
TR forms a heterodimer with the retinoid X receptor (RXR) and binds to T3 
responsive elements (TREs) in the promoter region of thyroid hormone-
responsive genes. Binding of T3 to its receptor effects a change in gene 
expression. In case of positive gene regulation, the T3-TR interaction induces 
the release of corepressors and the recruitment of coactivator, resulting in the 
stimulation of transcription (Jansen et al, 2005).  
 
5.4. Deiodinase 
 
The iodothyronine deiodinases constitute a highly specialized family of 
enzymes located in several tissues that metabolize thyroid hormone by 
removal of an iodine atom from either the outer (5´ position) or inner (5 
position) ring. Depending on the compound undergoing the reaction, 
deiodination can result in either the activation or inactivation of a thyroid 
hormone. Thus, the principal secreted product of the thyroid gland, the 
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prohormone T4 is converted to the biologically active T3 by 5´-deiodination. 
In contrast, 5-deiodination of T4 or T3 results in the formation of 3,3´,5´-
triiodothyronine (reverse T3) and 3,3´-diiodothyronine, compounds with little 
or no functional activity (Hernandez, 2003).
Most vertebrate species express three deiodinase enzymes, called types 1, 2, 
and 3 (DI, DII, DIII), which are encoded from three separate genes. All the 
deiodinases are membrane-bound proteins, approximately of 30 kDa in size, 
and contain the uncommon amino acid selenocysteine at the active catalytic 
site (St. Germain, 2001; Berry, 2002; Bianco, 2002; Kohrle, 2002).  
DI is most highly expressed in the adult liver, kidney, and thyroid gland. 
Although it has both outer and inner ring deiodinase activities, its major 
physiological function is the generation of plasma T3 (and clearance of 
plasma rT3). DII is expressed predominantly in the brain, pituitary gland, 
thyroid, skeletal muscule, and has exclusively a 5´-deiodinase. Although DII 
may contribute to circulating T3, it appears especially important for the local 
formation of T3 in these tissues, in particular in the brain. DIII functions as a 
pure 5-deiodinase are strongly expressed in the pregnant uterus, placenta, and 
fetal tissues as well as in adult brain and skin (Jansen et al, 2005).  
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Thyroid hormone metabolism in rat CNS is subject to a highly specific 
regulatory mechanism that differs substantially from that described in other 
tissues such as the liver or kidney. In these latter organs, most of the active 
iodothyronine compound T3 is taken up directly from the blood, whereas the 
T3 supply of the brain depends mainly on cellular uptake and intracellular 
deiodination of T4 (Crantz et al, 1982). 
 
5.4.1. Deiodinase type II 
 
Centrally, DII has been found to be highly expressed in the hypothalamus 
(Riskind et al, 1987; Tu et al, 1997; Diano et al, 1998a), specifically in the 
arcuate nucleus and the region surrounding the third ventricle. Most recently, 
it has been demonstarted that the cell types that produce DII are glial cells 
(Tu et al, 1997; Diano et al, 2003a), astrocytes, and tanycytes. In particular, 
tanycytes express one of the highest concentrations of DII activity and DII 
mRNA in the brain (Tu et al, 1997). Astrocytes are homogeneously 
distributed within the arcuate nucleus, contributing to the establishment of the 
blood brain barrier, while the cell bodies of tanycytes are predominately 
located on the floor and ventrolateral walls of the third ventricle, between the 
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rostral and caudal limits of the hypothalamic median eminence (Bruni, 1974; 
Krisch et al, 1978). Characteristic of tanycytes are apical microvilli and 
stereocilia that extend into the cerebrospinal fluid (CSF), and a basal process 
that ramifies into the underlying neuropil, encircling blood vessels in the 
adjacent arcuate nucleus, and terminating in numerous endfeet processes on 
or near fenestrated capillaries of the primary portal plexus in the external 
zone of the median eminence  (Bruni, 1974). Thus, tanycytes may provide a 
bidirectional, cytoplasmic conduit between the CSF in the third ventricle and 
the blood in the vascular elements of the arcuate nucleus and/or median 
eminence, allowing the movement of substances from one compartment to 
the other. Because DII activity and DII mRNA are not present in the 
hypothalamic PVN (Tu et al, 1997), it has been hypothesized that conversion 
of T4 to T3 by DII-expressing tanycytes may be part of the feedback 
regulation of the hypothalamic-pituitary-thyroid axis after uptake of T4 by 
tanycytes from CSF or vascular compartments and release of T3 back into the 
CSF, bloodstream, or median eminence (Tu et al, 1997). 
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 5.4.2. Deiodinase type II regulation 
 
Deiodinases are regulated by circulating thyroid hormone levels (Bianco et 
al, 2002). In particular, DII mRNA and activity are increased when 
circulating T4 levels are decreased, and the opposite occurs when T4 levels 
are increased. It has been suggested that the major role of the DII is to 
maintain T3 homeostasis, producing adequate intracellular levels of T3 to 
ensure all T3-dependent cellular functions in the tissue (Calvo et al, 1990; 
Leonard et al, 1981). In fact, in hypothyroid adult rats, the increased activity 
of DII is able to normalize T3 levels in the brain and other tissues after 
infusion of T4 in doses insufficient to adjust plasma T4 and T3 levels 
(Escobar-Morreale et al, 1995). In parallel with altered DII activity, failure of 
the thyroid gland [thyroidectomy or chemical inhibition of thyroid hormone 
production through 6-n-propyl-2-thiouracil (PTU), methimazole, or 
methimazole plus iopanoic acid] induces a modest elevation in hypothalamic 
TRH levels (Rondeel et al, 1992). In contrast, hypothyroid conditions 
induced by fasting coincide with suppressed production and release of TRH in 
the hypothalamic paraventricular nucleus and median eminence (Van 
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Haasteren et al, 1995). The central mechanism that underlies the emergence 
of this apparent paradox in thyroid feedback is ill defined. A different 
expression of type II deiodinase during fasting-induced hypothyroidism and 
hypothyroidism due to the failure of the thyroid gland may contribute to the 
development of this apparent paradox in thyroid feedback. During food 
deprivation, DII mRNA and activity are elevated in the hypothalamus. As 
expected, this increase coincides with a decrease in the plasma levels of T4 as 
well as T3. T4 replacement in these fasted animals, surprisingly, does not 
restore DII mRNA and activity to lower levels (Diano et al, 1998b). Thus, it 
would appear that, during fasting, the signal for the elevation of DII does not 
originate in the thyroid gland and, therefore, the lower circulating thyroid 
hormone levels under this condition are not the cause but, rather, the result of 
suppressed TRH production and release.   
 
5.5. Uncoupling proteins 
 
Uncoupling proteins (UCPs) are homologous proteins constituting a 
subfamily of mitochondrial anion carriers that are evolutionarily related and 
possibly derived from an ancestral protein that acted as a proton/anion carrier 
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(Lanni et al, 2003). The first of these proteins, UCP1, was discovered in 
brown adipose tissue, where it has a well-described role in thermogenesis. 
UCPs are located in the inner membrane of the mitochondria, and it is 
thought that their primary function is to leak hydrogen protons from the 
intermembrane space to the matrix of the mitochondria (Bouillaud et al, 
1985; Fleury et al, 1997). In the individual mitochondrion, these proteins may 
deprive the driving force of ATP synthase from catalyzing ATP synthesis, 
dissipate energy in the form of heat, diminish the production of superoxides, 
and decrease the likelihood of calcium entry to the mitochondrial matrix 
(Negre-Salvayre et al, 1997). However, despite decreased ATP production by 
an individual mitochondrion, the neurons overall will have more ATP 
available because uncoupling supports mitochondrial proliferation in the 
brain (Diano et al, 2003b) as well as in the adipose tissue (Rossmeisl, 2002).   
UCP1, the most well characterized UCP, is expressed solely in brown 
adipose tissue and is responsible for thermogenesis in small rodents (Nicholls 
et al, 1984). In the last few years, however, several other members of the 
UCP family have been discovered and found to promote partial uncoupling of 
oxidation from phosphorylation in vitro. These proteins include UCP2, 
UCP3, UCP4, and BMCP1/UCP5 (Fleury et al, 1997; Boss et al, 1997; Mao 
et al, 1999; Sanchis et al, 1998). The five putative UCPs differ greatly among 
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themselves, in tissue distribution and regulation, and may have distinct 
physiological roles. While UCP1 and UCP3 are expressed only in peripheral 
tissues (UCP1 in brown adipose tissue and UCP3 in skeletal muscle and the 
heart in humans), UCP4 and BMCP1 are predominantly expressed in the 
central nervous system (Mao et al, 1999; Sanchis et al, 1998), and UCP2 is 
expressed in muscle, adipose tissue, spleen, and the central nervous system 
(Fleury et al, 1997; Richard et al, 1998; Horvath et al, 1999; Diano et al, 
2000). 
 
5.5.1. Uncoupling protein 2 in the brain 
 
In the brain, in both rodents and primates, UCP2 is expressed predominantly 
in neuronal populations of subcortical regions that are involved in the central 
regulation of autonomic, endocrine, and metabolic processes. These regions 
include key brain stem and hypothalamic nuclei (Richard et al, 1998; Horvath 
et al, 1999; Diano et al, 2000). In rat extracts from hypothalamic regions with 
abundant UCP2 expression, the mitochondrial respiratory control ratio (RCR: 
ratio between state 3 and state 4) was found significantly lower than that 
measured in regions that lack UCP2 expression (the striatum-lateral thalamus 
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region; Horvath et al, 1999). On the one hand, the reduced RCR in the 
hypothalamus was attributable exclusively to an enhanced state 
4 mitochondrial respiration rate. State 4 respiration is caused only by the 
proton leak across the inner membrane, and mitochondria respiring in the 
absence of ADP or nonphosphorylating mitochondria. On the other hand, 
state 3 mitochondrial respiration rate (phosphorylating mitochondria in which 
the respiration is not controlled by proton leak) measured in the two regions 
did not differ. These results demonstrate regional variations in uncoupling 
activity in which higher mitochondrial uncoupling activity is positively 
correlated with UCP2 expression. The presence of decreased mitochondrial 
energy coupling efficiency (increased proton leak) in UCP2-containing brain 
regions supports the hypothesis that a thermogenic mechanism is intrinsic to 
distinct neuronal pathways (Horvath et al, 1999). Besides, brain tissue 
temperature in UCP2-containing brain regions has a significantly higher local 
level when compared to that in other sites or to the core body temperature. 
Brain sites other than those containing UCP2, such as the striatum and 
thalamus, exhibit a significant mitochondrial proton leak, which is consistent 
with the subsequent discovery of other putative brain uncouplers, such as 
UCP4 and BMCP1 (Mao et al, 1999; Sanchis et al, 1998). 
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UCP2 expression has been found in mitochondria of neurons, particularly in 
axon terminals, suggesting a direct role in interneuronal communication for 
mitochondrial uncoupling/thermogenic mechanism in circuits involved in the 
central regulation of homeostasis. Acute heat production in axon terminals 
could immediately accelerate synaptic transmission by affecting synaptic 
vesicle formation and traffic, neurotransmitter release and reuptake, and the 
tertiary structure of neuromodulators, as well as directly influence the 
postsynaptic membrane potential (Horvath et al, 1999). UCP2 and NPY have 
been found an abundant coexpression in the arcuate nucleus neurons 
(Horvath et al, 1999). In further support of the involvement of UCP2 in 
central metabolic pathways, UCP2 cells and processes were closely 
associated with leptin receptors, and after fasting, all of the c-fos-expressing 
neurons (marker for neuronal activity) were targeted by numerous UCP2-
containing boutons. In accordance with the projection of arcuate nucleus 
neurons, UCP2-containing axons were found to innervate other hypothalamic 
peptidergic systems that participate in metabolic regulation, including MCH- 
and orexin-producing cells. 
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5.6. Aim of the study 
 
 
In the CNS, the active form of the thyroid hormone, T3, derives from the 
cellular uptake and intracellular 5’-monodeiodination of T4 by DII. In the 
adult rat brain, high DII activity is present in the arcuate nucleus/median 
eminence region, and DII-producing cells are both astrocityes and tanicityes 
(Guadano-Ferraz et al, 1997; Diano et al, 1998a). Arcuate nucleus DII-
producing glial cells may actively participate in metabolism regulation 
because they are in close proximity to T3-targeted neurons, including those 
producing NPY, AgRP and POMC, all of which project onto the 
paraventricular TRH cells (Legradi and Lechan 1998; Fekete et al, 2000). In 
support of this theory, it has been found that arcuate nucleus DII activity is 
elevated during fasting (Diano et al, 1998b), a situation during which 
negative feedback of circulating thyroid hormones is diminished in the 
hypothalamus. 
The aforementioned observations give impetus to our hypothesis that it is the 
activation of arcuate nucleus DII by diminishing leptin and rising 
corticosterone levels that disrupts normal thyroid feedback during short-term 
food deprivation. On the one hand, we propose that during fasting, elevated 
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arcuate nucleus DII activity promotes both activation of the inhibitory 
NPY/AgRP and inhibition of the excitatory α-MSH projections onto 
paraventricular TRH neurons, thereby explaining the paradox that suppressed 
levels of circulating T4 and T3 parallel the inactivation of TRH. 
On the other hand, we propose that the interest in the interplay between DII 
and UCP2 in the regulation of the melanocortin system emerges when the 
proximity of these mechanisms in the arcuate nucleus is revealed. 
NPY cells express UCP2 and its expression and activity are regulated by 
thyroid hormones, T3 in particular. Furthermore, the activation of UCP2 may 
lead to elevated local temperature (Horvath et al, 1999), mitochondrial 
proliferation and ATP levels (Diano et al, 2003b), all of which enhance 
neuronal activity. We propose that, taken together, elevated corticosterone 
levels during negative energy balance trigger T3-regulated mitochondrial 
uncoupling in NPY/AgRP neurons, a key mechanism that allows NPY 
neurons to learn to remember the depletion of the energy stores. This 
learning/memory process within the melanocortin system entails 
mitochondrial proliferation and increased available ATP levels in NPY/AgRP 
neurons. This, in turn, enables elevated NPY/AgRP and suppressed POMC 
neuronal activity despite increasing metabolic signals in the circulation 
following re-feeding. 
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6. MATERIALS AND METHODS 
 
 
6.1. Experiment 1 
 
6.1.1. Animal treatment 
 
Seventy Sprague Dawley male rats from Taconic Farms Inc. (200-250gr) 
were used in this study.  
 
Animals were divided into 14 experimental groups: 
Group 1: Intact rats with food ad libitum (n=5) 
Group 2: Sham-operated rats with food ad libitum (n=5) 
Group 3: Adrenalectomized (ADX), ad libitum-fed rats (n=5) 
Group 4: ADX, low corticosterone-treated ad libitum-fed rats (n=5) 
Group 5: ADX, high corticosterone-treated, ad libitum-fed rats (n=5) 
Group 6: Leptin-treated, ad libitum-fed rats (L; n=5)    
Group 7: Intact rats fasted for 2 days (48 hours) (n=5) 
Group 8: 2-day fasted sham-operated rats (n=5) 
Group 9: 2-day fasted and ADX rats (n=5) 
Group 10: 2-day fasted, ADX and low corticosterone-treated rats (ADX+C; 
n=5) 
Group 11: 2-day fasted, ADX and high corticosterone-treated rats 
(ADX+C(h); n=5) 
Group 12: 2-day fasted and leptin-treated rats (L; n=5) 
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Group 13: 2-day fasted, adrenalectomized and high corticosterone and leptin-
treated rats (ADX+L+C(h); n=5) 
Group 14: 2-day fasted, ADX and leptin-treated rats (n=5) 
 
Bilateral adrenalectomy or a sham operation was performed under general 
anesthesia 1 week before starting the experiments. Immediately after surgery, 
adrenalectomized rats received drinking water containing 0.9% (w/v) NaCl.  
 
 
6.1.2. Corticosterone treatment 
 
Corticosterone treatment was initiated at the time of surgery. Corticosterone 
(0.2 mg/ml, low dose, or 0.6 mg/ml, high dose; Sigma St. Louis, MO) was 
dissolved in ethanol and this solution was added to the water yielding a final 
concentration of 2% ethanol. All the other groups non-treated with 
corticosterone were given similar drinking water without the hormone. To 
confirm that the daily water, and thereby, corticosterone intake reached the 
estimated amount and to ensure that the corticosterone supplementation did 
not alter drinking, we measured water consumption over 24 hrs.  
 
 
6.1.3. Leptin treatment 
 
At the time of the initiation of food deprivation (1 week after adrenalectomy), 
all groups were implanted subcutaneously with Alzet micro-osmotic pumps 
(Model 1003D, 1 µl per hour, 3 days; Alza, Palo Alto, CA) which were filled 
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with either PBS (as control in groups 1-5 and 7-11) or 500 ng/µl leptin 
(groups 6, 12-14; recombinant rat leptin, PeProTech Inc., Rocky Hill, NJ). 
 
 
6.1.4. DII enzymatic activity 
 
The animals were sacrificed and the mediobasal hypothalamus (defined 
rostrally by the optic chiasma, caudally by the mamillary bodies, laterally by 
the optic tract and superiorly by the apex of the third ventricle) was dissected 
and stored at -80ºC prior to DII activity measurements. DII activity was 
measured based on the release of radioiodide from the 125I-labeled substrate. 
Using 100,000 cpm of L[125I] T4 (PerkinElmer Life Sciences, Boston MA) 
for each sample, an incubation mixture containing 100 µg tissue homogenate 
in 0.1 M potassium phosphate buffer (pH=7.0), 1 mM EDTA in the presence 
of 5 nM T4, 30 mM DTT, 1 mM PTU and 1 µM T3 (to inhibit the inner ring 
deiodination of T4 due to the presence of D3 activity) were incubated in 
duplicate at 37°C for 1 h. The reactions were stopped by addition of 50 µl 
ice-cold 5% BSA followed by 200 µl 20 % ice-cold trichloroacetic acid and 
centrifuged at 4000 g for 20 min. The supernatant was further purified by 
cation exchange chromatography on 1.6 ml Dowex 50 W-X2 (100-200 mesh; 
Sigma Chemical Co., St. Louis, MO). The iodide was then eluted with 2x1 
ml 10% glacial acetic acid and counted in a gamma counter. Enzymatic 
deiodination was corrected for non-enzymatic 125I production as determined 
in blank incubations without homogenates and multiplied by 2 to account for 
the random labeling and deiodination for the 3’ and 5’ positions in labeled 
T4. Enzymatic activity is expressed in femtomoles of 125I- released per hour 
per milligram of protein. 
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For the determination of proteins, the bicinchonic acid assay (BCA Protein 
Assay, Pierce Rockford, IL) was employed. 
 
 
6.1.5. Hormone measurements 
 
Plasma total T4 (TT4), free T4 (FT4), T3 and thyroxine binding capacity 
(TBC) were measured by the Microparticle Enzyme Immunoassay (MEIA), 
using AxSym System in the Clinical Chemistry Laboratory of the Yale-New 
Haven Hospital. Plasma leptin, corticosterone  was measured using RIA kits 
from Linco Research Inc. (St. Charles, MO) according to the manufactures 
protocols. Due to the high number of samples measured in duplicates, assays 
conducted in our laboratory were run at different time. However, to ensure 
the consistency of the results, samples from fed and fasted intact rats were 
always included in every assay as control. 
 
 
6.1.6. Statistical analysis 
 
 
For each experiment, means were compared between experimental groups 
using one-way analysis of variance (ANOVA) with mean comparisons by the 
Student-Newman-Keuls Method. A level of confidence of p< 0.05 was used 
to determine significant differences. 
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6.2. Experiment 2 
 
6.2.1. Hypothalamic TRH mRNA levels 
 
Twenty Sprague-Dawley male rats (200-250g BW; Taconic Farms, Inc.) 
were implanted with a cannula into the third ventricle (Bregma -0.8 mm). 
Animals were divided into 2 experimental groups: a control group (n=10) 
was infused with 0.9% saline, while the second group (n=10) was infused 
with 10-7M IOP diluted in 0.9% saline (Alzet micro-osmotic pump 1µl/hour, 
3 days). All the animals were infused for the duration of the experiment. 
Twenty-four hours after the implantation of the pump, the animals were 
further divided in the following groups: n=5 infused with 0.9% saline and fed 
ad libitum ; n=5 infused with 0.9% saline and fasted for 48 hours; n=5 
infused with 10-7M IOP and fed ad libitum; n=5 infused with 10-7M IOP and 
48 hour fasted. The animals were then perfused and processed for semi-
quantitative in situ hybridization histochemistry.   
An 826 bp fragment of complementary DNA (cDNA) of TRH was amplified 
based on the RT-PCR reaction, using specific oligonucleotide primers 
derived from the coding region of the rat TRH sequence. Total RNA was 
extracted from the hypothalamus by guanidium thiocyanate-phenol-
chloroform method using TriZol reagent (Life Tecnologies, Grand Island, 
NY) and transcribed using the First-Strand cDNA Synthesis Kit (Pharmacia 
Biotech, Piscataway, NJ). Linearized DNA was transcribed using T7 
polymerase (antisense cRNA probe) and T3 polymerase (sense cRNA probe; 
Riboprobe Combination System T3/T7, Promega Corporation, Madison, WI) 
and labeled with 35S-UTP (Amersham; 10 mCi/ml). 
 64
The purified cRNA probes was heated at 80°C for 2 minutes with 500 µg/ml 
yeast tRNA and 50 µM DTT in water before being diluted to an activity of 
5.0 x 107 dpm/ml with hybridization buffer containing 50% formamide, 0.25 
M sodium chloride, 1x Denhardt’s solution and 10% dextran sulfate. Sections 
with this hybridization solution (150 µl/slide) were incubated overnight at 
50°C. Following hybridization, the slides were washed in 4xSSC prior to 
RNase digestion (20 µg/ml for 30 min at 37°C), rinsed at room temperature 
in decreasing concentrations of SSC that contained 1 mM DTT (2x, 1x, 0.5x; 
10 minutes each) to a final stringency of 0.1xSSC at 65°C for 30 minutes. 
After dehydration in increasing alcohols, the sections were exposed to β-max 
hyperfilm (Amersham) for 5 days before being dipped in Kodak NTB liquid 
emulsion diluted 1:1 with distilled water. The dipped autoradiograms was 
developed 21 days later with Kodak D-19 developer, fixed, and the sections 
counterstained through the emulsion with hematoxylin. Sections were 
examined under brightfield and darkfield illumination.  
The density of the hybridization product was assessed in the different 
experimental groups. In order to digitally analyze, quantitate and compare the 
amount of TRH mRNA, an Image-1/AT image processor (Universal Imaging 
Corporation, West Chester, PA) using an Olympus IMT-2 inverted 
microscope with dark field optics (Olympus Corporation, Lake Success, New 
York) and a Hamamatsu CCD camera (Hamamatsu Photonics, Hamamatsu, 
Japan) was employed. Six sections per animal were selected from the same 
area to assess the intensity of the hybridization product.  The total surface 
covered by the hybridization product was assessed within a test region 
measuring 2x105 mm2 that contains the paraventricular nucleus.  The 
threshold for measurement was assessed for each slide by determining the 
background labeling in the nearby ventromedial nucleus.   
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6.2.2. Hypothalamic T3 measurements 
 
Twenty male Sprague-Dawley rats (200-250 gr. BW; Taconic Farm, Inc) 
were used in this study.  Each animal was implanted with one cannula into 
the third ventricle (Bregma -0.8 mm) connected to a micro-osmotic pump 
(Alzet Corp., Palo Alto, CA; 1.0 µl/hr for 3 days). Animals were divided into 
4 experimental groups: group 1 (n=4) and group 2 (n=4) infused with 0.9% 
saline, group 3 (n=4) and group 4 infused with 10-7M IOP diluted in 0.9% 
saline. Rats were infused for the duration of the experiment. Twenty-four 
hours after implantation, group 2 and 4 were food-deprived for 48 hrs.  All 
animals were then sacrificed and the hypothalamus was collected and 
immediately frozen and stored at –80 ˚C.  
Triiodothyronine (T3) was extracted from the hypothalamus by adding 
methanol 95% containing PTU 10-4 M. Tissues were homogenized and 
centrifuged at 13000 rpm and the pellets re-suspended twice using methanol 
solution. The supernatants were evaporated to dryness and resuspended in 
GAB buffer (0.2 M Glycine/0.13 M Acetate with 0.02% BSA). T3 was 
determined by radioimmunoassay system (RIA). Samples and standard curve 
were incubated at 4oC with polyclonal antibody against T3 (Fitzgerald 
Industries International, Concord MA) in RIA buffer GAB. Three days later, 
10,000 cpm of radiolabeled [125I]-T3 (Specific activity 2200Ci/mmol; 
PerkinElmer Life Sciences, Boston MA) was added to each tube. After two 
days of incubation, a rabbit gamma globulin (Jackson ImmunoResearch 
Laboratories) diluted in 0.1 M EDTA and 16% polyethylene glycol with goat 
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antirabbit IgG (Antibodies Incorporated, Davis CA) in GA buffer (0.2 M 
Glycine/0.13 M Acetate) was added to precipitate the antibody- T3 complex. 
After centrifugation the precipitates were counted in a γ-counter. 
T3 is expressed in pg per mg of weight tissue. 
 
 
6.2.3. Double immunocytochemistry 
 
Adult C57Bl6 mice carrying GFP in NPY/AgRP neurons (Pinto et al., 2004) 
were used in this study. Animals were perfused transcardially with 4% 
paraformaldehyde, 15% picric acid and 0.1% glutaraldehyde in 0.1M 
phosphate buffer (PB; pH 7.35). Brain sections were pre-incubated in 1% 
H2O2 and 1% sodium borohydride, before overnight incubation with rabbit 
anti-DII (Diano et al., 2003b). After the secondary antibody (biotinylated 
goat antirabbit IgG; Vector Laboratories, Inc., Burlingame, CA) the sections 
were incubated with either avidin-biotin-peroxidase (ABC Elite Kit, Vector 
Laboratories, Inc.) or avidin-Texas Red for immunofluorescent microscopy.  
For electron microscopy, the immunolabeling for DII was visualized with a 
modified version of the nickel-diaminobenzidine (Ni-DAB) reaction (15 mg 
DAB, 0.12 mg glucose oxidase, 12 mg ammonium chloride, 600 µl 0.05 M 
nickel ammonium sulfate, and 600 µl 10% ß-D-glucose in 40 ml PB) and 
were further incubated with a mouse anti-GFP antibody (Molecular Probes, 
Eugene OR). The immunoreactivity for GFP was visualized with DAB 
resulting in a brown reaction product. Sections were then postosmicated (1% 
OsO4), dehydrated through increasing ethanol concentrations and embedded 
in Durcupan (Electron Microscopy Science, Fort Washinghton, PA, USA). 
Ribbons of ultrathin sections (Reichert-Jung Ultramicrotome) were collected 
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on Formvar-coated single slot grids, and examined using a Philips CM-10 
electron microscope. 
 
 
6.2.4. Brain mitochondria preparation and uncoupling activity measurements  
 
Twenty-four C57B6 mice were used in this study and divided in the 
following groups: 8 mice were injected i.p. with T3 (5 ug/30g BW); 8 mice 
were injected i.p. with saline; 8 mice were fasted for 24 hours and 8 rats were 
fed ad libitum. Mice injected with saline or T3 were sacrificed 6 hours after 
the injection. The hypothalamus was dissected and homogenized in the 
isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% fatty acid-free 
BSA, 20 mM HEPES, 1 mM EGTA, pH adjusted to 7.2 with KOH). Protein 
concentrations were determined with a BCA protein assay kit (Pierce, 
Rockford, IL). Mitochondrial respirations were assessed using a Clark-type 
oxygen electrode (Hansatech Instruments, Norfolk, UK) at 37°C with 
pyruvate and malate (5 and 2.5 mM) as oxidative substrates in respiration 
buffer (215 mM mannitol, 75 mM sucrose, 0.1% fatty acid-free BSA, 20 mM 
HEPES, 2 mM MgCl, 2.5 mM KH2PO4, pH adjusted to 7.2 with KOH). After 
the addition of ADP and oligomycin, an inhibitor of H+-transporting ATP 
synthase, UCP-mediated proton conductance was measured as increased fatty 
acid-induced respiration which was then compared with state 4 respiration 
induced by oligomycin. 
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6.2.5. Fasting and refeeding 
 
Five male DII knockout, 5 wild type, 5 UCP2 knockout, and 5 wild type mice 
were fasted for 24 hours.  Food was replaced after 24 h at which time body 
weight and core body temperature were recorded and food intake was 
measured in a 60 minute period following re-feeding.  
 
 
6.2.6. Semi-quantitative RT-PCR 
  
RT-PCR was used to assess mRNA levels of UCP2 in DII KO animals (n=5) 
compared to those in their wild type controls (n=5), and in T3-treated rats 
compared to those in saline treated rats. Animals were sacrificed and 
hypothalami were dissected. Total RNA was isolated using Trizol. cDNA 
was synthetized by a First-Strand cDNA Kit (Amersham Biosciences, 
Piscataway, NJ).  
Primers to amplify UCP2 were:  
forward 5’-CTACAAGACCATTGCACGAGAGG-3’ and  
reverse 5’-AGCTGCTCATAGGTGACAAACAT-3’ (396 bp).  
As internal control a 201 bp fragment of GAPDH  
5’-CTCATGACCACAGTCCATGC-3’ and reverse  
5’-CACATTGGGGGTAGGAACAC-3’ was amplified.  
Reactions were analyzed by gel electrophoresis and intensity of the bands 
was analysed by Gel-Pro Analyzer software (Media Cybernetics, Silver 
Spring, MD). 
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 6.2.7. Quantification of mitochondria in GFP-NPY/AgRP cells of the arcuate 
nucleus  
 
C57Bl6 adult mice carrying GFP in NPY/AgRP neurons and GFP-NPY 
ob/ob mice were perfused as described above and their brains were processed 
for GFP immunolabeling for electron microscopic examination. The unbiased 
stereological methods for mitochondria number assessment that were used 
are based upon our published paper (Pinto et al, 2004). A series of sections 
was defined with equal spacing of a known distance, and the volume of the 
structure of interest was estimated using the Cavalieri method (Gundersen 
and Jensen, 1987). The counts obtained represent the number of mitochondria 
per unit volume of the structure of interest. These counts were then corrected 
for the total volume of the structure obtained with the Cavalieri method, 
yielding a value for total mitochondrial number for the cell class and 
structure sampled.  
 
6.2.8. Statistical analysis 
 
 
For each experiment, means were compared between experimental groups 
using one-way analysis of variance (ANOVA) with mean comparisons by the 
Student-Newman-Keuls Method. A level of confidence of p< 0.05 was used 
to determine significant differences. 
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7. RESULTS 
 
7.1. Experiment 1 
 
7.1.1. Hormone measurements 
 
Plasma levels of corticosterone, leptin, TT4, FT4, T3 and TBC are shown in 
Table 1 for fasted animals and in Table 2 for ad libitum fed rats.  
The forty-eight hour fasting increased corticosterone levels in the intact rats 
(Table 1) compared to fed controls (Table 2). Adrenalectomy with or without 
leptin replacement in fasted rats resulted in undetectable levels of 
corticosterone in their plasma (Table 1). Corticosterone administration at low 
doses (ADX+C) in fasted rats significantly increased circulating 
corticosterone to physiological levels (value not significantly different from 
intact fed rats in Table 2). The levels of corticosterone in fasted 
adrenalectomized rats with high dose of corticosterone (ADX+C(h)) and in 
fasted rats treated with leptin and high corticosterone (L+C(h)) were 
comparable to the level of the intact fasted rats.  Leptin administration to 
fasted animals reduced corticosterone to the levels of intact fed rats.  
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In ad libitum fed animals (Table 2), adrenalectomy was successfully 
performed as shown by the undetectable levels of corticosterone. 
Corticosterone replacement to physiological levels was conducted 
successfully as was corticosterone replacement to fasted levels.  
Fasting induced a significant decrease in plasma leptin levels (Table 1) 
compared to ad libitum fed rats (Table 2). Adrenalectomy of fed animals 
significantly decreased leptin levels (Table 2) although they were statistically 
higher than the leptin levels of fasted rats. Corticosterone administration at 
low and high doses increased leptin levels in fed ADX animals (Table 2). 
Only high doses of corticosterone significantly increased plasma leptin 
(Table 1).  
Leptin levels in fasted ADX+L, and L groups (Table 1) were comparable to 
leptin level in the intact fed group (Table 2).  
Total T4 as well as free T4 in fasted intact rats was significantly lower 
compared to fed intact animals. Moreover, none of the treatments in any of 
the fasted groups could elevate TT4 and FT4 levels to those of fed intact rats. 
Fasted rats with high levels of circulating corticosterone (intact, ADX+C(h) 
and L+C(h)) showed significantly lower levels of TT4 compared to animals 
with no detectable or just physiological levels of corticosterone (Table 1). In 
contrast, no statistically significant values were observed in the circulating 
levels of free T4 between any of the fasted rats. 
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In fed animals, TT4 as well as FT4 showed a significant decrease in the 
group treated with the high dose of corticosterone compared to all other 
groups with undetectable, low or physiological levels of corticosterone 
(Table 2).  
T3 levels in fasted animals also showed significant decreases compared to 
those in fed rats. In fasted animals, plasma T3 in ADX+C(h) and leptin 
treated rats showed values similar to those in intact fed rats. In addition, ADX 
rats treated with corticosterone to physiological levels showed an increase in 
circulating T3 compared to intact fasted rats. This increase was significantly 
lower than that observed in leptin treated and ADX+C(h) groups (Table 1).  
Fasted rats showed a thyroxine binding capacity (TBC) that, although slightly 
higher, was not significantly different from that observed in fed animals. 
Moreover, undetectable levels of corticosterone resulted in a significant 
increase in TBC both in fasted and fed animals, although ADX fed rats with 
physiological levels of corticosterone showed an elevated TBC compared to 
that in the intact fed group. 
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 FASTED 
RATS 
CORT 
µg/dl 
Leptin 
ng/ml 
TT4 
µg/dl 
FT4 
ng/dl 
T3 
ng/dl 
TBC 
µg/dl 
Intact 38.1±6.8b,c,d,f 0.3±0.2 d,e,f,g 3.1±0.14 
b,c,d,f
2.9±0.1 33±3.0 b,c,d,e,f 5.1±0.4 b,d
ADX NDa,c,e,f,g 0.2±0.1 c,d,e,f,g 4.6±0.12d a,e,g 2.6±0.1 49.8±2.1 a,c,e,f 7.9±0.5 a,c,e,f,g
ADX+C 11.2±2.2a,b,d,e,g 0.6±0.2 b,d,e,f,g 4.3±0.13a,e,g 2.9±0.2 59.5±1.1 a,b,d,e,f,g 5.5±0.6 b,d
ADX+L NDa,c,e,f,g 2.9±0.1 a,b,c,e,g 4.9±0.32a,e,g 2.7±0.3 49.3±2.5 a,c,e,f 8.6±1.1 a,c,e,f,g
ADX+C(h) 31.8±2.8b,c,d,f 1.7±0.4a,b,c,d,g 3.6±0.1 b,c,d,f 3.1±0.5 70.3±4.5 a,b,c,d,g 5.6±0.7 b,d
L 11.6±1.1a,b,d,e,g 2.1±0.3a,b,c,d,g 4.5±0.2a,e,g 3.2±0.2 70.0±4.4 a,b,c,d,g 5.07±0.3 b,d
L+C(h) 30.4±4.7b,c,d,f 6.2±0.1a,b,c,d,e,f 3.5±0.8 b,c,d,f 1.6±1.0 39±13.3 c,e,f 5.7±1.0 b,d
 
Table 1 Effects of ADX, corticosterone replacement at low or high doses, and /or leptin 
administration on hormone levels of food deprived animals (n=5 for each group).  
Results are expressed as mean±SEM.  
aP<0.05 compared to Intact.  
bP<0.05 compared to ADX.  
cP<0.05 compared to ADX+C.  
dP<0.05 compared to ADX+L.  
eP<0.05 compared to ADX+C(h). 
fP<0.05 compared to L.  
gP<0.05 compared to L+C(h) CORT=Corticosterone; TT4= Total T4; FT4=Free T4; T3= 
3,5,3’ triiodothyronine; TBC= Thyroxine binding capacity; ND= non detectable 
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FED 
RATS 
CORT 
µg/dl 
Leptin 
ng/ml 
TT4 
µg/dl 
FT4 
ng/dl 
T3 
ng/dl 
TBC 
µg/dl 
Intact 11.6±5.0b,d,e 2.9±0.3 b,c,d,e 5.5±0.8 d  3.6±0.4d 76.0±6 d  4.5±0.7b,c 
ADX NDa,c,d,e 1.2±0.03 a,c,d,e 5.2±0.2 d 3.2±0.1d 70.33±4.1 d 6.1±0.3a,e 
ADX+C 11.9±3.5b,d,e 4.2±0.7a,b 5.1±0.6 d 4.4±0.1 b,d,e 79.7±8.9 d 6.4±0.4a,e 
ADX+C(h) 24.2±1.4a,b,c,e 5.6±0.7a,b 2.7±0.5 a,b,c,e 2.2±0.3a,b,c,e 60.3±6.4a,b,c,e 5.2±0.6b,c 
L 3.3±0.2a,b,c,d 5.8±2.1a,b 4.1±0.5 d 3.1±0.1c,d 71.3±3.4d 4.8±0.3b,c 
 
 
Table 2 Effects of ADX, ADX plus corticosterone replacement at low or high doses, 
and leptin administration on hormone levels of ad libitum  fed animals (n=5 for each 
group).  
Results are expressed as mean±SEM.  
aP<0.05 compared to Intact. 
bP<0.05 compared to ADX. 
cP<0.05 compared to ADX+C.  
dP<0.05 compared to ADX+C(h).  
eP<0.05 compared to L.   
CORT= Corticosterone; TT4= Total T4; FT4=Free T4; T3=3,5,3’ triiodothyronine; 
TBC= Thyroxine binding capacity; ND= non detectable. 
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7.1.2. DII enzymatic activity 
 
Fasting in intact animals (94.33±2.69 fmol/h/mg protein) increased DII 
enzymatic activity compared to that in ad libitum fed rats (80.5±4.95 
fmol/h/mg protein; Fig. 1). 
In ad libitum fed rats, DII activity (Fig. 2A) of intact and sham-operated 
animals (80.5±4.95 and 78.76±1.23 fmol/h/mg protein, respectively) did 
not show any significant changes compared to those in ADX (86.39 
±0.99 fmol/h/mg protein) rats or ADX rats treated with corticosterone at 
either low (85.45±1.87 fmol/h/mg protein) or high doses (85.63±3.08 
fmol/h/mg protein). 
On the other hand, in fasted animals (Fig 2B), ADX significantly 
reduced DII activity (78.67±3.35 fmol/h/mg protein) compared to that in 
intact and sham-operated rats (94.33±2.69 and 98.33±2.87 fmol/h/mg 
protein, respectively). When corticosterone was replaced in ADX fasted 
rats, DII activity showed a dose-dependent increase, with the greater 
elevation at the high dose of corticosterone, that mimics the serum level 
of the intact fasted rats (88.25±0.87 fmol/h/mg protein and 96.27±1.46 
fmol/h/mg protein, in low dose and high dose, respectively). Indeed, at 
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the high dose of corticosterone, DII activity did not significantly differ 
from that in intact fasted animals (96.27±1.46 fmol/h/mg protein in 
corticosterone treated compared to 94.33±2.69 fmol/h/mg protein in the 
intact rats). 
This difference in the effect of corticosterone on DII activity in fed 
compared to fasted rats, led us to analyze the consequences of leptin 
administration in the same paradigm (Fig. 3). When leptin was 
administered to fed animals, no changes were observed between this 
group and their control fed rats (80.5±4.95 and 78.42± 4.21 fmol/h/mg 
protein). On the other hand, leptin administration to fasted animals 
decreased DII activity (76.52±1.61 fmol/h/mg protein) compared to that 
in their control intact fasted rats (94.33±2.69 fmol/h/mg; Fig.4) and 
reduced DII activity to the levels of fed control rats (80.5±4.95 
fmol/h/mg protein; Fig. 3). Leptin treatment to fasted rats also reduced 
corticosterone plasma levels further supporting the fact that, during 
negative energy balance, the decrease in plasma leptin and the 
simultaneous increase in corticosterone levels are necessary for the 
elevation of DII activity. 
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We examined the effect of the administration of leptin, corticosterone or 
both on DII activity of fasted rats (Fig. 4) and compared the following 
groups: intact fasted, intact fasted plus leptin, ADX fasted, ADX fasted 
plus leptin and ADX fasted plus high corticosterone levels. As described 
above, leptin administration to fasted animals restored DII activity to the 
level of intact fed rats. ADX rats fasted for 48 hrs and ADX fasted rats 
treated with leptin did not show any differences in DII activity compared 
to that in the intact rats given leptin. When we administered high doses 
of corticosterone to fasted ADX rats, DII activity was statistically 
elevated to the levels of intact fasted rats and when these animals 
(ADX+C at high doses) were treated with leptin to physiological levels, 
we did not observe the increase in DII activity that was seen without 
leptin treatment (Fig. 4). 
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Fig.1 Hypothalamic DII activity expressed in femtomoles of I-per hour 
per mg of protein in intact ad libitum fed rats (n=5) and intact fasted rats 
(n=5). Using one-way ANOVA, results are expressed as the mean ± 
SEM. * P<0.05 compared to fed intact. 
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Fig. 2 A. Hypothalamic DII activity measurements in all ad libitum fed 
rats (n=5 for each group) either left intact or sham operated or 
adrenalectomized (ADX) or ADX plus corticosterone treatment at low 
doses (ADX+C) or at high doses (C(h)). No significant differences were 
observed between these groups. B. Bar graph showing hypothalamic DII 
activity measurements in all fasted animals. Results are expressed as 
mean± SEM.* P<0.05 compared to Intact, Sham and ADX+C(h).  
# P<0.05 compared to ADX. 
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Fig. 3 Hypothalamic DII activity measurements in intact ad libitum fed rats 
(n=5), intact ad libitum fed rats plus leptin treatment (Intact fed+L; n=5), 
intact fasted animals (n=5) and intact fasted rats plus leptin treatment (Intact 
fasted +L; n=5). While leptin treatment to fed animals does not affect 
hypothalamic DII activity, leptin replacement to fasted rats induces a 
significant decrease as compared to intact fasted rats in DII measurement.  
Results are expressed as mean± SEM.* P<0.05 compared to Intact fed, Intact 
fed+L and Intact fasted +L animals. 
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Fig. 4 Hypothalamic DII activity measurements in all fasted animals. 
Intact and adrenalectomized plus corticosterone treatment at high dose 
(ADX+C(h)) show a statistically significant elevation of DII activity 
(*P<0.05) compared to the intact plus leptin treatment (Intact+L), 
adrenalectomized (ADX), ADX plus leptin treatment (ADX+L) and 
leptin plus corticosterone treatment at high dose (L+C(h)). Results are 
expressed as mean± SEM. 
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7.2. Experiment 2 
 
 
7.2.1. Hypothalamic TRH mRNA levels 
 
In situ hybridization for TRH mRNA in the paraventricular nucleus of the 
hypothalamus of saline infused rats showed that fasting induces a decrease in 
TRH mRNA levels compared to those in fed control animals. The TRH 
mRNA levels in saline treated fasted rats was 68% ± 4.7 of that seen in saline 
treated fed animals (P<0.05; Fig. 5). When the animals were treated with 
IOP, fasting blunted this decrease in TRH mRNA levels being 89% ± 7.8 of 
those seen in IOP treated fed animals (P>0.05; Fig. 5).   
 
7.2.2. Hypothalamic T3 measurements 
 
We previously showed that during food deprivation, DII activity levels are 
increased in the hypothalamus. To assess whether this elevation in activity 
also induces increased tissue levels of T3, we performed T3 measurements in 
the hypothalamic tissue of fasted and fed animals. Moreover, to determine 
whether the effect of IOP in blunting TRH mRNA decline during fasting is 
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due to a change in the tissue T3, we assessed hypothalamic T3 levels in IOP 
infused rats that were either fasted or fed ad libitum. Hypothalamic T3 levels 
were significantly higher in saline-treated fasted rats (2.32±0.13 pg/mg wet 
tissue) compared to those in the saline-treated ad libitum fed animals 
(1.71±0.03 pg/mg wet tissue; Fig.6). On the other hand, in IOP-infused rats, 
food deprivation did not affect hypothalamic T3 levels (1.81±0.03 pg/mg wet 
tissue) that were not significantly different from the levels of the fed animals 
(1.95±0.04 pg/mg wet tissue). 
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Fig. 5 In situ hybridization for TRH mRNA in the PVN revealed that while fasting 
suppressed TRH mRNA levels in the saline-treated animals (P<0.05), ICV IOP 
(dissolved in saline) injections blunted the fasting-induced decline in TRH mRNA 
levels of the PVN. Results are expressed as mean± SEM. *p<0.05 compared to 
saline-treated fed, IOP-treated fed and fasted rats. 
 
 85
 0
1
2
3
 ICV saline               ICV IOP
*
pg
/m
g 
w
et
 ti
ss
ue
Fed FedFasted Fasted
 
Fig. 6: Graph showing hypothalamic T3 levels in fed or fasted 
rats after ICV injection of saline or IOP (n=4 for each group). 
Results are expressed as mean± SEM. *p<0.05. 
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7.2.3. Double immunocytochemistry for DII and GFP 
 
This study was performed to show the existence of a direct apposition 
between DII expressing glial cells and perikarya of GFP-NPY neurons in the 
arcuate nucleus. Immunostaining for DII in GFP-NPY transgenic mice 
revealed a close association between DII-producing glial processes and 
NPY/AgRP neurons (Fig. 7).  Electron microscopic examination showed 
(Fig. 8 panel B) tanycytes immunostained for DII in contact with a GFP-NPY 
immunoreactive cell.  Thus, if DII is present in astrocytic processes, then it is 
reasonable to assume that arcuate nucleus cells, including neurons, may be 
exposed to locally formed T3.  This observation reveals that locally formed 
T3 by glial cells may have direct access to the melanocortin system, 
particularly the NPY/AgRP neurons. This provides a basis for neuronal glial 
interaction in metabolism regulation as DII activity is upregulated during 
fasting.  
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Fig. 7 Immunostaining for DII in GFP-NPY transgenic mice 
revealed close associations between DII-producing glial 
processes and NPY/AgRP neurons. This observation revealed 
that locally formed T3 by glial cells may have direct access to the 
melanocortin system, particularly the NPY/AgRP neurons.  
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Fig. 8 Electron photomicrograph showing (panel B) tanycytes 
immunostained with DII (arrow heads) in contact with a GFP-NPY 
immunoreactive cell. A and C are high power magnification 
photomicrographs showing 2 tanycytes immunopositive for DII in contact 
(arrow heads) with an axon hillock (AH) of a GFP-NPY cell in the arcuate 
nucleus of the hypothalamus. Panel D shows another tanycyte 
immunostained for DII in contact (arrow head) with the same GFP-NPY 
cell of the arcuate nucleus.  
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7.2.4. Measurements of UCP2 uncoupling activity and RNA messenger 
 
It has been shown that in peripheral tissue, T3 regulates mitochondrial 
uncoupling activity (Lanni et al, 1997; Masaki et al, 1997). To investigate 
whether T3 triggers mitochondrial uncoupling activity also in the brain, we 
measured the uncoupling activity in the hypothalamic mitochondria of T3-
treated and fasted mice compared to that in saline-treated and fed control 
mice, respectively. UCP2 is a highly active H+ transporter in the presence of 
CoQ10 and free fatty acids. Whereas CoQ10, the electron acceptor for 
complexes I and II of the electron transfer chain, is constitutively expressed 
in mitochondria, endogenous free fatty acids are sequestered by BSA. Thus, 
isolated mitochondria were incubated with palmitic acid (300 µM), and the 
increase in respiration was expressed relative to state 4 respiration induced by 
the ATP synthase inhibitor oligomycin to give an index of uncoupling 
activity. T3-treated and fasted mice showed a significant increase in 
uncoupling activity compared to that in their controls (+50% and +30%, 
respectively; Fig. 9). Moreover, T3 treatment induced also an elevation of 
hypothalamic UCP2 mRNA (Fig. 10). 
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Fig. 9 Fatty acid-induced mitochondrial uncoupling. Exposure to the free 
fatty acid palmitate induces increased uncoupling activity in fasted and 
T3-treated mice compared to fed and saline-treated mice, respectively. 
*p<0.05 compared to fed, and **p<0.001 compared to saline-treated 
mice. 
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Fig. 10 RT-PCR from representative samples of sali
treated mice shows an elevation of hypothalamic UC
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7.2.5. Quantification of mitochondria in GFP-NPY/AgRP cells of the arcuate 
nucleus 
 
To study whether elevated mitochondrial uncoupling triggers mitochondria 
proliferation in the hypothalamus, we assessed the mitochondria number in 
two models of negative energy balance, fasted and ob/ob mice. We found 
that in both fasted and ob/ob animals the number of mitochondria in 
NPY/AgRP neuron was elevated compared to that in their fed controls or 
wild type, respectively (Fig. 11). In particular, in NPY-AgRP neurons of 
fasted mice the mitochondrial number was 91% greater compared to that in 
their fed controls, while in the ob/ob mice the increase was about 113% 
compared to that in their wild type controls. 
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Fig. 11 GFP-NPY neurons in the hypothalamic arcuate nucleus of a fed 
mouse and a fasted mouse (upper micrographs) and a wild type and an 
ob/ob mouse (lower micrographs). Red points indicate some of the 
mitochondria which appear to be more numerous in fasted and ob/ob 
NPY/AgRP neurons compared to the values of their respective controls.  
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7.2.6. Fasting and refeeding in DII KO animals 
 
We analyzed the acute responses of DII knockout animals to a 24 hour 
fasting regimen. Five male DII knockout and 5 male wild type animals were 
fasted.  Food was replaced after 24 h at which time body weight and core 
body temperature were recorded and food intake was measured in a 60-
minute period following re-feeding. Twenty-four hour fasting reduced the 
body weight of both wild type and DII KO animals.  However, the weight 
reduction in DII KO animals unmasked a significant difference in body 
weight between KO and wild type animals in which DII KO animals 
weighed less (24.11±0.66 g) than their wild type littermates (27.98±0.52 g; 
Fig. 12). The core body temperature of both KO and wild type animals 
declined during the fasting, and here again, fasting unmasked a significant 
difference in core body temperature between groups, in which DII KO 
animals had significantly lower core body temperature after fasting 
(34.9±0.35 ºC) than their wild type littermates (35.78±0.18 ºC). Based on the 
differences in these parameters, it is reasonable to indicate that lack of DII 
increases the depth of negative energy balance following food deprivation. 
More pronounced negative energy balance should trigger a more robust 
rebound effect following re-feeding. Strikingly, however, food intake at the 
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end of 24 h fasting, was significantly lower in DII KO animals compared to 
that in wild type littermates both in the first (0.39±0.06 g in DII KO; 
0.56±0.014 in the wild type) and second 30-minute period after re-feeding 
(0.065±0.005 g in D2KO; 0.14±0.015 g in wild type; Fig. 12). 
 
7.2.7. UCP2 messenger RNA in the hypothalamus of DII KO mice 
 
RT-PCR showed (Fig.13) that in the DII KO mice the levels of UCP2 mRNA 
(0.9±0.1 arbitrary density) are significantly lower than those in their wild type 
controls (1.3±0.09 arbitrary density). This evidence further supports our central 
hypothesis that an interplay between glial DII and neuronal UCP2 in the 
hypothalamus is responsible for the rebound feeding. 
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 Fig. 12 Acute responses of DII knockout mice to a fasting regimen. 
After 24 h, DII KO mice weighed less than their wild type littermates, 
and DII KO animals had significantly lower core body temperature than 
their wild type littermates. Food intake at the end of 24 h fasting, was 
significantly lower in DII KO animals compared to wild type littermates 
both in the first and second 30-minute period after re-feeding.
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Fig. 13 RT-PCR shows that in the DII KO mice the levels of UCP2 
mRNA are significantly lower than their wild type controls.  
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7.2.8. Fasting and refeeding in UCP2 KO mice 
  
We analyzed the acute response of UCP2 KO animals to 24 h fasting.  The 
initial feeding response of UCP2 KO mice after food deprivation was 
diminished (0.52±0.13 g; 0.35±0.03 g) compared to that in the fasted wild type 
littermates (0.86±0.09 g; 0.54±0.05 g; Fig. 14). Note that the normal feeding 
behavior of these animals is not affected nor do these animals show visible signs 
of gross metabolic alterations (data not shown).   
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Fig. 14 Diminished rebound feeding in UCP2 KO mice. 
After 24 h fasting, food intake of UCP2 KO mice was lower compared to 
the values of wild type littermates. 
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8. DISCUSSION 
 
 
The results of our study demonstrate that inverse changes in circulating levels 
of the stress hormone, corticosterone, and the metabolic signal, leptin, are 
critical triggers for increased DII activity in the hypothalamus during food 
deprivation. In fasted rats, adrenalectomy significantly reduces hypothalamic 
DII activity to the level of the animals given food ad libitum. Conversely, 
corticosterone administration to ADX fasted rats increases DII activity in a 
dose-dependent manner. When leptin was administered to fasted rats, DII 
activity was reduced to the level of intact fed animals. A comparison of 
plasma leptin and corticosterone levels showed, in fact, that the leptin-treated 
fasted group had hormone values similar to those in intact fed animals. 
Moreover, leptin administration to ADX fasted rats with or without 
corticosterone replacement showed no changes in the levels of DII compared 
to those in fasted ADX animals (Fig. 4), indicating that the decrease in 
plasma leptin allows a corticosterone-dependent increase in DII activity 
during fasting.   
Our results show that in fasted ADX rats, when corticosterone is replaced to 
physiological levels, DII activity is significantly lower than that found in 
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fasted intact, fasted sham-operated, as well as ADX fasted rats with high dose 
corticosterone replacement (Fig. 2B).  Although an indirect effect of 
corticosterone on TRH levels via DII activation might be hypothesized, there 
is direct evidence that glucocorticoids affect TRH synthesis through the 
presence of glucocorticoid receptors on TRH-producing cells (Ceccatelli et 
al, 1989), and the existence of the glucocorticoid-responsive element in the 
promoter region of the pro-TRH gene (Lee et al, 1988). 
The current results clearly indicate that circulating leptin and corticosterone 
levels play a key regulatory role in DII activity in fasted animals.  It is also 
clear, however, that neither of these hormones is critical for baseline 
expression of DII activity since neither of them appeared to affect 
hypothalamic DII levels in fed animals (Fig.2A and 3).  
When leptin is administered to fasted animals, it induces an increase of TRH 
mRNA to the level of that in intact animals (Legradi et al, 1997). Therefore, 
it has been suggested that leptin may directly act on TRH neurons since the 
long form of leptin receptors is widely distributed in the hypothalamus and 
has been found to be expressed in TRH cells (Fekete et al, 2002). We 
propose, however, that leptin-restored TRH mRNA levels in the 
hypothalamic paraventricular nucleus might be due, at least in part, through 
their effect in lowering corticosterone levels (see Table 1) and, consequently, 
DII activity in the arcuate nucleus/median eminence region (Fig. 3).  
 102
The results of this study suggest that activation of hypothalamic DII during 
fasting contributes to elevated local T3 production, which, in turn, could 
trigger suppression of TRH mRNA levels in the paraventricular nucleus. 
To block DII activity, we employed IOP, a potent competitive and 
irreversible inhibitor of DII in vivo as well as in vitro (Larsen et al, 1979; 
Obregon et al, 1980; Courtin et al, 1985; Goswami, and Rosenberg, 1986). 
In our study, we observed that IOP had a different effect in all the parts of the 
brain examined. The intracerebroventricular infusion of IOP in fasted rats 
showed that IOP at a concentration of 10-7M can selectively inhibit the 
activity of DII in the hypothalamus without interfering with its activity in 
other brain regions or in the pituitary gland (data not shown). We propose 
that this differential effect is the consequence of the accessibility of IOP. 
Because the cannulae in the third ventricle were positioned in the anterior 
portion of the hypothalamus (Bregma -0.8), it is reasonable to hypothesize 
that the strongest effect of IOP at the lower dose (10-7 M) was found in the 
hypothalamus, compared to that in the hippocampus, cerebellum, and 
pituitary gland.   
Although IOP treatment did not reduce hypothalamic T3 levels in fed 
animals, it did prevent T3 elevation induced by fasting. We found that in fed 
animals treated with IOP hypothalamic, T3 levels were slightly elevated 
compared to those in the saline-treated fed animals and this could be the 
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reason for the slight suppression of TRH levels in the IOP-treated fed group. 
While it may appear to be a paradox, we suggest that the elevated 
hypothalamic T3 levels in the IOP-treated fed group could be due to 
increased transport of circulating T3 to the hypothalamus (rather than local 
formation).  However, fasting-induced DII increase was blocked by IOP, and 
hence the diminished suppression of TRH.  
Thus, we propose that the previously unsuspected existence of hypothalamic 
hyperthyroidism in the face of systemic hypothyroidism during fasting may be 
responsible both for the decline of TRH mRNA levels and for the reversal of 
negative feedback of the thyroid axis. 
The arcuate nucleus has been found to contain an abundant number of thyroid 
receptor-producing neuronal nuclei (Lechan et al, 1993), as well as 
populations producing various regulatory peptides and neurotransmitters, 
such as neuropeptide Y, opioid peptides, growth hormone releasing hormone, 
and dopamine, all of which are known to influence the production and release 
of TRH (Judd and Hedge, 1982; Liao et al, 1991; Fekete et al, 2000). Also 
demonstrated has been the existence of a monosynaptic pathway between the 
arcuate nucleus that contains DII-producing glial cells, and the 
paraventricular TRH neurons that project to the median eminence with direct 
access to fenestrated capillaries (Diano et al, 1998b). In addition, it has been 
shown (Diano et al, 1998c; Legradi and Lechan, 1998) that the arcuate 
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nucleus NPY/AgRP neurons provide a massive inhibitory input on TRH cell 
bodies and proximal dendrites via symmetric synapses. Another study 
(Legradi and Lechan, 1999) has also reported that TRH cells are 
symmetrically contacted by nerve terminals containing AgRP, which is co-
produced in the NPY arcuate neurons. In the present study, we show that 
activation of DII induces alterations in arcuate nucleus T3 levels and may be 
responsible for the decrease in TRH mRNA levels during fasting. Thus we 
hypothesize that the increase in T3 levels during food deprivation could 
affect and alter neuropeptide expression in leptin-responsive arcuate neurons 
that strongly project to paraventricular TRH neurons.  Studies are underway 
to delineate this signaling modality in the hypothalamic regulation of the 
thyroid axis. 
By light and electron microscopic examination, we showed a direct 
relationship between DII-containing, and hence triiodothyronine (T3)-
producing, glial elements and components of the melanocortin system, 
including the NPY/AgRP-expressing arcuate nucleus neurons. On the one 
hand, DII-produced T3 can have the immediate effect of increasing 
mitochondrial ATP by enhancing electron transport in the cytochrome chain 
that could contribute to the acute activation of NPY cells during fasting 
(Takahashi and Cone, 2005). On the other hand, we have shown that NPY 
cells express UCP2, the expression level and activity of which are enhanced 
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by thyroid hormones, T3 in particular. Activation of UCP2 may lead to 
elevated local temperature, mitochondrial proliferation and increased ATP 
levels, which together could enhance neuronal activity in a sustained manner. 
This sustained elevation of ATP due to mitochondrial proliferations is the 
mechanism that would enable AgRP neurons to have increased firing after 
refeeding.  
In support of this theory, we have shown that DII KO, as well as UCP2 KO 
mice, have an impaired response to negative energy balance. After 24 hours 
of food deprivation, both DII KO and UCP2 KO mice consumed less food 
than their wild type controls did. In addition, we also showed that DII KO 
mice have reduced levels of UCP2 mRNA in their hypothalamus.  
Under normal conditions (satiety), peripheral anorexigenic hormones, such as 
leptin, control the melanocortin system (Elmquist, 2001). In fasting, 
orexigenic hormones, such as ghrelin, will reverse the tone of the 
melanocortin system in which NPY/AgRP neuronal activity will dominate 
(Zigman and Elmquist, 2003).  At the same time, elevating corticosteroid 
levels will trigger DII activity (Diano et al, 1998b) and local T3 production, 
which will trigger UCP2 production and activity in mitochondria of 
NPY/AgRP neurons. The elevated activity of NPY/AgRP neurons will 
suppress POMC tone. That this cascade is triggered by corticosteroids is 
supported by the study of Drazen et al (2003) in which adrenalectomy was 
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observed to alter the sensitivity of the melanocortin system. On the basis our 
study, we suggest that by the time of re-feeding, activated UCP2 will 
proliferate mitochondria in NPY/AgRP neurons which, in turn, will be a 
critical factor in maintaining increased firing of these orexigenic cells so that 
food intake will remain elevated and POMC neuronal firing suppressed 
subsequent to refeeding, at a time when neither orexigenic nor anorexigenic 
circulating signals dominate. 
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